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ABSTRACT
Ischemic stroke is one of the leading causes of death and disability worldwide 
but the treatment options remain limited. Ischemic stroke, or cerebral infarct, 
occurs when blood flow to a focal brain region is restricted due to arterial 
blockage. Lack of oxygen and energy leads to rapid neuronal death in the 
ischemic region and to an inflammatory response via activation of brain-
resident immune cells, microglia, and infiltration of peripheral leukocytes 
after ischemia-induced blood-brain barrier damage. Acute neuroprotective 
strategies need to be executed within a few hours after ischemia induction to 
be effective and have not proven successful in clinical trials. However, 
inflammation persists in the post-stroke brain and modulation of post-stroke 
inflammation could provide a therapeutic strategy with a large time window. 
Inflammation has both beneficial and harmful effects on injury progression 
but our understanding of many aspects of post-stroke inflammation remains 
incomplete. 
We characterized the neuroinflammatory response in the rat distal middle 
cerebral artery occlusion (dMCAo) model that was used to induce cortical 
infarcts in this thesis work. We found long-lasting inflammation and presence 
of phagocytic cells for up to 4 months after dMCAo, especially in the ipsilateral 
thalamus. We also found delayed neuronal loss occurring in the ipsilateral 
thalamus between 1-2 weeks after dMCAo due to connecting projection 
pathways between the cortex and the thalamus.  
Mesencephalic astrocyte-derived neurotrophic factor (MANF) is an 18 kDa 
endoplasmic reticulum luminal protein that is neuroprotective in 
experimental ischemic stroke models and has been associated with 
immunomodulatory properties. However, the knowledge of MANF’s recovery-
promoting effects, mechanism of action, and endogenous expression pattern 
after cerebral ischemia are still limited. Thus, we characterized the 
endogenous MANF protein expression pattern in the dMCAo model and in 
ischemic stroke patient brains. Notably, we found that MANF protein 
expression is strongly induced in activated immune cells in the infarcted 
rodent and human brains. We also studied intracerebral post-stroke MANF 
therapy via viral delivery and recombinant protein injection and found that 
MANF promotes functional recovery when administered into the brain 2 days 
post-stroke as an adeno-associated viral (AAV) vector or as a recombinant 
protein starting 3-7 days post-stroke. Post-stroke MANF treatment did not 
alter the infarct size but the AAV-MANF therapy induced a transient increase 
in the number of phagocytic cells and innate immunity-related transcript 
levels in the peri-infarct area. In addition, we conducted a proof-of-concept 
study using intranasal MANF delivery to explore alternative delivery routes for 
  
administering the blood-brain barrier impermeable MANF protein. Pre-stroke 
intranasal MANF therapy decreased infarct volume and behavioral deficits. 
These data suggest a theoretical potential for intranasal MANF therapy, but 
bioavailability requires further improvement. 
As another approach, we investigated the efficacy of repeated post-stroke 
intranasal (+)-naloxone delivery in the dMCAo model. (-)-Naloxone is a small 
molecule drug which has been in clinical use for opioid overdose for decades 
and studied in the acute treatment of ischemic stroke because of its opioid 
receptor antagonizing effect. More recently, (-)-naloxone and its opioid 
receptor inactive (+) enantiomer have been shown to possess anti-
inflammatory effects and to reduce microglial activation. (+)-Naloxone 
therapy, started one day post-stroke and continued for 7 days, decreased the 
infarct size and microglia/macrophage activation, and reduced behavioral 
deficits.  
This work broadens knowledge of the post-stroke neuroinflammation and 
secondary pathology of the thalamus in the cortical infarct model and shows 
for the first time that endogenous MANF protein is expressed in the activated, 
phagocytic immune cells in the infarcted human brain. This work also provides 
evidence on the recovery-promoting effects of post-stroke MANF and (+)-
naloxone therapy and links both therapies with immunomodulatory functions. 
 
  
TIIVISTELMÄ
Aivoinfarkti on maailmanlaajuisesti yksi yleisimmistä kuolinsyistä sekä 
toimintakykyä heikentävistä tekijöistä, mutta sen hoitokeinot ovat rajalliset. 
Aivoinfarkti aiheutuu valtimotukoksesta, joka estää veren virtauksen 
paikalliselle aivoalueelle. Hapen ja energian puute johtaa nopeasti 
hermosolujen kuolemaan aivoalueella sekä tulehdukselliseen vasteeseen 
aivojen paikallisten immuunisolujen, mikroglian, aktivoiduttua sekä 
perifeeristen valkosolujen tunkeuduttua aivokudokseen rikkoutuneen veri-
aivoesteen läpi. Akuutit solukuoleman vähentämiseen tähtäävät hoidot täytyy 
toteuttaa muutaman tunnin kuluessa infarktista. Aivoinfarktiin liittyvä 
inflammaatio on kuitenkin pitkäkestoinen ja tämän tulehdusvasteen 
muokkaaminen voisi tarjota hoitokeinon, jolla on laaja aikaikkuna. 
Inflammaatiolla on sekä myönteisiä että haitallisia vaikutuksia vaurion 
etenemisen kannalta, mutta ymmärryksemme näistä on monelta osin vielä 
puutteellista. 
Karakterisoimme aivojen inflammatorisen vasteen rotan distaalisen 
keskimmäisen aivovaltimon okkluusio-mallissa, jota käytettiin aivokuoren 
infarktin aiheuttamiseen tässä väitöstyössä. Havaitsimme pitkäkestoista 
inflammaatiota ja fagosytoivia soluja aivoissa vielä 4 kuukauden päästä 
infarktista erityisesti vaurion puoleisella talamuksen aivoalueella. 
Havaitsimme myös viivästynyttä hermosolukuolemaa vaurion puoleisessa 
talamuksessa 1-2 viikon kuluessa infarktista johtuen aivokuoren ja 
talamuksen yhdistävistä hermoradoista. 
Keskiaivojen astrosyyttiperäinen hermokasvutekijä (MANF) on 18 kDa:n 
kokoinen solulimakalvoston sisäinen proteiini, joka suojaa vaurioilta 
aivoinfarktin kokeellisissa malleissa ja jolla on immuunivastetta sääteleviä 
ominaisuuksia. Tiedot MANF:n toipumista edistävistä vaikutuksista, 
vaikutusmekanismista sekä ilmentymisestä aivoinfarktin jälkeen ovat 
kuitenkin vielä puutteelliset. Karakterisoimme MANF-proteiinin 
ilmentymisen aivokuoren infarktimallissa sekä aivoinfarktipotilaiden 
aivonäytteissä ja havaitsimme MANF:n ilmentymisen lisääntyvän 
voimakkaasti aktivoituneissa immuunisoluissa sekä jyrsijöiden että potilaiden 
aivoissa infarktin jälkeen. Tutkimme myös infarktin jälkeen aivoinjektiona 
annetun MANF-hoidon vaikutusta rottien toipumiseen ja havaitsimme 
virusvektorina 2 päivää infarktin jälkeen annetun MANF:n sekä proteiinina 3-
7 päivää infarktin jälkeen aloitetun MANF-annostelun edistävän 
toiminnallista toipumista. Infarktin jälkeinen MANF-hoito ei vaikuttanut 
infarktin kokoon, mutta virusvektorina annettu MANF lisäsi tilapäisesti 
fagosytoivien solujen määrää sekä immuunivasteeseen liittyvien geenien 
ilmentymistä infarktia ympäröivällä alueella. Lisäksi suoritimme rotilla 
  
alustavan tutkimuksen käyttämällä intranasaalista MANF-annostelua 
selvittääksemme vaihtoehtoisia tapoja veri-aivoesteen läpäisemättömän 
MANF-proteiinin annostelemiseksi. Ennen infarktia intranasaalisesti annettu 
MANF pienensi infarktin kokoa sekä vähensi toiminnallisia vajeita. Tämä 
viittaa intranasaalisen MANF-hoidon teoreettiseen toimivuuteen, mutta 
MANF:n biologinen hyötyosuus vaatii parantamista. 
Toisena lähestymistapana tutkimme infarktin jälkeisen toistetun 
intranasaalisen (+)-naloksonin annostelua aivokuoren infarktimallissa. (-)-
Naloksoni on opioidiyliannostuksen hoitoon jo kauan kliinisessä käytössä 
ollut pienimolekyylinen yhdiste, jota on tutkittu aivoinfarktin akuutissa 
hoidossa opioidireseptoreja salpaavan vaikutuksensa takia. (-)-Naloksonin 
sekä sen opioidireseptoreihin sitoutumattoman (+)-enantiomeerin on 
hiljattain todettu omaavan anti-inflammatorisia vaikutuksia sekä vähentävän 
mikroglian aktivaatiota. Havaitsimmekin päivä infarktin jälkeen aloitetun 
viikon kestävän (+)-naloksoni-hoidon pienentävän infarktin kokoa sekä 
vähentävän mikroglian ja makrofagien aktivaatiota sekä rottien toiminnallisia 
vajeita. 
Tämä väitöstyö laajentaa tietämystämme aivoinfarktin jälkeisestä 
tulehduksellisesta vasteesta sekä talamuksen sekundäärisestä vauriosta 
aivokuoren infarktimallissa ja osoittaa ensimmäisen kerran MANF-proteiinin 
ilmentyvän aktivoituneissa, fagosytoivissa immuunisoluissa 
aivoinfarktipotilaiden aivoissa. Väitöstyö todistaa myös infarktin jälkeen 
annetun MANF- ja (+)-naloksoni-hoidon edistävän rottien toipumista sekä 
liittää molemmat hoidot immuunivastetta sääteleviin ominaisuuksiin.                                            
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1 INTRODUCTION
Stroke is the second leading cause of death and a major cause of disability 
worldwide, making the economic burden of stroke-related costs enormous. 
Age is the most important risk factor for stroke and with the aging population, 
the incidence of stroke is expected to further increase. Yet, treatment options 
are limited and there is no drug treatment that would promote functional 
recovery after stroke. Currently, the only pharmacological therapy for stroke 
in the US and Europe is the thrombolytic agent alteplase that needs to be 
administered routinely within 4.5 hours from the onset of ischemic stroke. 
This narrow time window can be accomplished in only a minority of patients. 
Thus, it is vital to develop a drug therapy that would aid recovery and could be 
administered even days after the initial ischemic attack. 
Approximately 80% of stroke cases are caused by ischemia which usually 
results from local thrombosis or an embolus blocking a major cerebral artery. 
Oxygen and energy depletion leads rapidly to neuronal death in the ischemic 
core area. Also, the immune cells of the brain, microglia, are activated and 
peripheral immune cells infiltrate the ischemic area after blood-brain barrier 
(BBB) damage. Inflammation is one of the key players in the pathogenesis of 
ischemic stroke but is also an essential element in brain repair mechanisms, 
and modulation of post-stroke inflammation as a therapeutic target has gained 
an increasing amount of attention during the past years. Post-stroke 
inflammation is long-lasting and could thus provide a wide therapeutic time 
window. 
Mesencephalic astrocyte-derived neurotrophic factor (MANF) is a 
cytoprotective protein residing in the endoplasmic reticulum (ER) lumen and 
is an important regulator of ER homeostasis (Lindahl et al., 2017). MANF is 
neuroprotective in the rat middle cerebral artery occlusion model when given 
before stroke as a protein or via a viral vector (Airavaara et al., 2009; 
Airavaara et al., 2010). Interestingly, MANF has been shown to possess 
immunomodulatory effects (Chen et al., 2015; Neves et al., 2016).  
Naloxone is an old drug with relatively newly found anti-inflammatory 
properties (Das et al., 1995; Liu et al., 2000c; Hutchinson et al., 2008). The (-
) enantiomer of naloxone is a potent opioid receptor antagonist in clinical use 
for opioid overdose (Iijima et al., 1978). Naloxone has good brain penetration 
properties and has become one of the most used drugs for opioid overdose, 
and is nowadays given most often intranasally due to ease of administration 
(Rzasa Lynn & Galinkin, 2018). However, the (+) enantiomer has a very low 
affinity for opioid receptors (Iijima et al., 1978) but possesses similar anti-
inflammatory effects as (-)-naloxone, making (+)-naloxone an interesting 
candidate with more specificity towards inflammation.  
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As deeper knowledge of post-stroke inflammation and novel therapies for 
ischemic stroke are desperately needed, this thesis focused on investigating 
post-stroke inflammation and the effects of post-stroke MANF and (+)-
naloxone therapy.
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2 REVIEW OF THE LITERATURE
2.1 ISCHEMIC STROKE 
 
Stroke encompasses two major types of stroke: ischemic stroke and 
hemorrhagic stroke. Cerebral ischemic stroke is caused by local thrombosis or 
embolism that leads to a lack of blood supply to a focal area in the brain, 
whereas hemorrhagic stroke is caused by intracerebral or subarachnoid 
hemorrhage (Hankey, 2017). The majority, about 80%, of strokes are caused 
by ischemia (Meretoja et al., 2010).  
The term “stroke” was first introduced by a physician named William Cole 
in 1689 (Cole, 1689) but it took more than 200 years to become an established 
term in medicine. The term “apoplexy”, derived from ancient Greek and 
meaning “to strike suddenly”, was used until the 20th century to describe 
stroke (Engelhardt, 2017). The first written description of apoplexy was 
documented by Hippocrates approximately 2,500 years ago (Engelhardt, 
2017). Hippocrates’ definition of stroke still stands: “It is impossible to remove 
a strong attack of apoplexy, and not easy to remove a weak attack” (Marks, 
1818), as modern medicine is still challenged by limited treatment options for 
stroke.  
Globally, and in Finland, stroke is the second leading cause of death after 
ischemic heart disease (Mortality & Causes of Death, 2016). In Finland, there 
are approximately 18 000 new cases of ischemic stroke every year (Aivoliitto, 
2020). The costs of stroke treatment are huge, and in Finland encompassed  
3% of the entire national healthcare expenditure in 2017 with costs of 640 
million euros total related to stroke (Luengo-Fernandez et al., 2019). Within 1 
year post-stroke, the fatality of ischemic stroke is 24%, while 64% of the 
patients are able to live at home, and 12% remain in institutional care 
(Meretoja et al., 2010). The incidence of ischemic stroke increases with age 
(Seshadri et al., 2006). Other risk factors for ischemic stroke are hypertension, 
dyslipidemia, carotid stenosis, atrial fibrillation, diabetes, cigarette smoking, 
excessive alcohol consumption, drug use, obesity, unhealthy diet, physical 
inactivity, depression, and psychosocial stress (Autret et al., 1987; Lewington 
et al., 2002; O'Donnell et al., 2010; Fonseca & Ferro, 2013). The neurological 
symptoms of focal ischemic stroke are dependent on the brain region that is 
affected by the ischemia and have a sudden onset. The symptoms typically 
include unilateral weakness or numbness of arm or leg, facial weakness, 
speech disturbances, visual field defects or visual loss, and vertigo (Hankey, 
2017). 
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Rapid recanalization is the foundation of ischemic stroke therapy. The 
importance of rapid thrombolysis was depicted well in a study that found every 
15 min decrease in treatment delay provided 1 month of extra disability-free 
life (Meretoja et al., 2014). Currently, the only drug approved for clinical use 
in Europe and the US is the recombinant tissue plasminogen activator (rtPA) 
alteplase that is used for thrombolysis and in general needs to be administered 
within 4.5h from the symptom onset (Hacke et al., 2008). According to recent 
studies, thrombolysis is beneficial in some patients for up to 9h after the 
symptom onset (Thomalla et al., 2018; Campbell et al., 2019).  However, due 
to a narrow time window and contraindications, only a minority of all ischemic 
stroke patients receive thrombolysis, leaving the majority of the patients 
without the possibility for drug treatment. Finland is one of the top countries 
in thrombolysis rates with 15% of ischemic stroke patients receiving 
thrombolysis (Stevens et al., 2017) and with “door-to-needle time” of 26 min 
on average (Meretoja et al., 2014). A mechanical procedure for recanalization, 
endovascular thrombectomy, can be performed at least until 6h after the 
symptom onset (Goyal et al., 2016; Hankey, 2017) and in some patients up to 
24h (Albers et al., 2018; Nogueira et al., 2018). Hemicraniectomy can be 
performed in patients with large, malignant middle cerebral artery infarctions 
to reduce intracranial hypertension caused by cerebral swelling (Yang et al., 
2015). In this patient group, the hemicraniectomy decreases mortality and can 
increase functional outcome (Yang et al., 2015). After the ischemic stroke, 
current therapies aim to prevent the renewal of infarction primarily with 
antithrombotic agents and treatment of known risk factors, such as 
hypertension, dyslipidemia, and obesity (Hankey, 2017). Rehabilitative 
therapy is based on physiotherapy and neuropsychological rehabilitation. 
However, recovery is often slow and incomplete and there is a great need for a 
drug therapy that could promote the functional recovery of the stroke 
survivors. 
2.1.1 PATHOPHYSIOLOGY OF ISCHEMIC STROKE
 
Focal ischemic stroke is caused by hypoperfusion in the brain territory 
supplied by the occluded artery, and the extent of cerebral injury depends on 
the severity and duration of hypoperfusion [see in (Dirnagl et al., 1999; 
Durukan & Tatlisumak, 2007; Brouns & De Deyn, 2009)]. The infarct core is 
dependent on the supply of the occluded artery, and the neuronal cells are 
rapidly and permanently lost due to ischemia. It is estimated that each minute 
during ischemia, 1.9 billion neurons are lost (Saver, 2006). The core is 
surrounded by an ischemic penumbra, where the collateral vessels are able to 
compensate for the hypoperfusion to some extent. However, if the 
hypoperfusion continues, the infarct core also expands to the penumbra area 
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(Baron, 1999).  The main mechanism of cell death in the infarct core is 
necrosis, while apoptosis dominates in the penumbra (Sairanen et al., 2006). 
The focal cerebral hypoperfusion causes oxygen and energy depletion in the 
surrounding cerebral tissue and triggers the “ischemic cascade” (Figure 1). 
Cerebral tissue is extremely dependent on the continuous blood supply as the 
brain has no energy store (Durukan & Tatlisumak, 2007). The ischemic 
cascade initiates from adenosine triphosphate (ATP) depletion that leads to 
failure of the ATP-dependent Na+/K+- and Ca2+/H-ion pumps and subsequent 
depolarization of cells. The depolarization activates voltage-gated Ca2+ 
channels and results in the release of excitatory amino acids, especially 
glutamate, to the extracellular space. By activating glutamate receptors, 
glutamate induces Ca2+ influx into the cell and further exacerbates the increase 
of intracellular Ca2+ levels. Excess extracellular glutamate and K+ also trigger 
depolarization in the surrounding penumbra area which leads to permanent 
damage if long-lasting (Dijkhuizen et al., 1999).  
Simultaneously, elevated intracellular Ca2+ concentration induces 
activation of several Ca2+ dependent enzymes (ex. kinases, proteases, lipases, 
and synthases) and production of cytotoxic compounds, such as reactive 
oxygen species (ROS) and nitric oxide (NO). The free radicals damage various 
cellular structures and can trigger apoptosis, and the activation of proteases 
and lipases leads to degradation of the plasma membrane and necrosis. 
Moreover, the activation of matrix metalloproteinases and damage to vascular 
endothelium leads to disruption of the BBB and subsequent vasogenic edema 
as well as leukocyte infiltration. In an animal model of transient ischemic 
stroke, the BBB already opens 25 min after reperfusion and remains open up 
to 5 weeks post-stroke (Strbian et al., 2008; Abo-Ramadan et al., 2009). The 
level of BBB disruption is dependent on the infarct size (Abo-Ramadan et al., 
2009). Reperfusion is the aim of ischemic stroke therapy but can paradoxically 
exacerbate the cerebral injury via increased ROS formation in ischemia-
compromised mitochondria combined with inadequate antioxidant 
production during ischemia, subsequent activation of the pro-inflammatory 
transcription factor NF-κB (nuclear factor kappa-light-chain-enhancer of 
activated B cells) in the vascular endothelium, and enhanced neutrophil 
adhesion [see in (Schaller & Graf, 2004)]. Reperfusion can also induce lipid 
peroxidation and membrane damage, and surprisingly, increase apoptosis 
which is an energy-dependent process.  
Increased intracellular Ca2+ levels and ATP deficiency disrupt the ER Ca2+ 
homeostasis by inducing Ca2+ release from the ER via ryanodine and inositol 
trisphosphate receptor channels and via failure of the ATP-dependent 
sarcoplasmic/endoplasmic Ca2+-ATPase pump that maintains the high Ca2+ 
levels within the ER under physiological conditions  [see in (Bodalia et al., 
2013)]. Disruption of ER Ca2+ homeostasis leads to the accumulation of 
unfolded proteins in the ER lumen and triggers ER stress and the unfolded 
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protein response (UPR). In general, the adaptive responses of the UPR aim to 
restore ER homeostasis but, when failing, apoptosis can be induced [see in 
(Hetz, 2012)]. However, the role of ER Ca2+ depletion and UPR in the 
modulation of cell death in ischemic stroke is not well known.  
 
Figure 1. Simplified schematic image of pathophysiological events occurring after 
focal cerebral ischemia in the infarct core. Ischemia causes a lack of oxygen and 
energy (ATP) which leads to ion pump failure and increased intracellular Na+ and 
Ca2+ levels and extracellular K+ levels. Elevated Ca2+ results in mitochondrial damage, 
ER stress, activation of enzymes that produce ROS and NO causing further damage 
to different cellular organs and degradation of cellular membranes. Elevated Na+
results in cellular edema and the cell membrane is depolarized after ion pump failure, 
leading to glutamate release and further depolarization of peri-infarct region cells as 
well. The BBB is enzymatically degraded and allows the infiltration of peripheral 
leukocytes into the brain parenchyma. Also, resident microglia are activated and 
further exacerbate the inflammatory cycle. NOX2 and TLR4 levels are increased in 
the activated microglia and contribute to ROS and cytokine production.
ATP, adenosine triphosphate; BBB, blood-brain barrier; ER, endoplasmic reticulum; NO, nitric 
oxide; NOX2, NADPH oxidase 2; ROS, reactive oxygen species; TLR4, Toll-like receptor 4
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2.1.2 BRAIN REPAIR MECHANISMS AFTER ISCHEMIC STROKE
 
Ischemic stroke is associated with significant spontaneous recovery that 
occurs mainly within the first 2 months post-stroke and may continue later in 
patients with severe deficits (Nakayama et al., 1994). Intrinsic brain repair 
mechanisms are initiated soon after ischemic injury, already within 1-2 days 
in rodents (Zhang et al., 2001; Hayashi et al., 2003) and 5 days in patients, 
continuing for months or more (Krupinski et al., 1994). These processes are 
orchestrated together by different cell types in the brain to create a repair-
promoting environment and consist of angiogenesis, neurogenesis, 
synaptogenesis and white matter remodeling, and neuroinflammation [see in 
(Venkat et al., 2018)]. In a wider sense, this intrinsic ability of the brain to 
remodel for optimized function can be considered plasticity and functional 
recovery occurs when other brain regions adjacent to the ischemic lesion and 
in the contralesional hemisphere take functions of the damaged neuronal 
networks [see in (Murphy & Corbett, 2009; Guggisberg et al., 2019)].  The 
timing of these reparative processes and different therapeutic approaches after 
ischemic stroke are depicted in Figure 2. The biological processes in the stroke 
recovery phase differ substantially from the processes in the hyperacute and 
acute phase targeted by neuroprotective treatments, and these differences 
should be considered when conducting stroke recovery trials (Corbett et al., 
2017). 
Figure 2. Timeline of pathophysiological and reparative processes and therapeutic 
approaches after ischemic stroke. The goal of reparative treatments is to enhance 
endogenous plasticity (shown in pointed purple line). Adapted from (Dobkin & 
Carmichael, 2016; Bernhardt et al., 2017).
 
Angiogenesis, meaning the formation of new microvessels, is a highly 
regulated phenomenon and the gene expression of angiogenic factors is 
already induced 1h after cerebral ischemia in the middle cerebral artery 
occlusion (MCAo) model in mice (Hayashi et al., 2003). In ischemic stroke 
patients, angiogenesis has been shown to occur in the penumbra and linked 
with better survival (Krupinski et al., 1994).  
Neurogenesis occurs in the post-stroke brain in the rodent MCAo model 
(Arvidsson et al., 2002) and has been reported in the immunostained 
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penumbra area of the infarcted human cortex as well  (Jin et al., 2006). Using 
a photothrombotic stroke model in mice, neurogenesis was recently shown to 
be necessary for post-stroke functional recovery (Liang et al., 2019). However, 
a study using radiocarbon determination found no neurogenesis in the 
infarcted human cortex, making the role of endogenous neurogenesis in the 
human post-stroke brain unclear (Huttner et al., 2014).  
In an ischemic stroke model, markers of axonal growth have been reported 
to increase in the peri-infarct cortex already 3 days after distal middle cerebral 
artery occlusion (dMCAo) in rats and synaptogenesis to occur at 14 days post-
dMCAo and onwards in the peri-infarct cortex as well as in the contralateral 
cortex (Stroemer et al., 1995). Formation of new synapses and white matter 
remodeling, including remodeling of axonal connections and 
oligodendrogenesis-induced remyelination, are important for restoring 
neuronal connections in the damaged brain after ischemic stroke and have 
been linked to behavioral recovery. 
Neuroinflammation has a role in creating a pro-regenerative environment 
after ischemic injury, and glial cells, including astrocytes and microglia, 
support the repair mechanisms by producing trophic factors, such as brain-
derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor 
(GDNF) and vascular endothelial growth factor (VEGF) [see in (Hermann & 
Chopp, 2012)].  
Boosting the endogenous repair mechanisms has created one line of 
research for stroke therapy. The time window of potential neuroreparative 
therapies is rather large, and thus appealing from a clinical point of view. The 
main therapeutic lines investigated are based on exogenous cell 
transplantation, stimulation of endogenous neurogenesis, and neuronal 
reprogramming.  
2.2 INFLAMMATION AFTER ISCHEMIC STROKE
Ischemic stroke induces activation of brain-resident immune cells, microglia, 
and infiltration of peripheral leukocytes into the brain parenchyma. These 
cells have different roles and time course in the progression of ischemic 
cerebral injury (Figure 3). 
Microglia were first described in 1919 by a Spanish physician Pío del Río-
Hortega (Sierra et al., 2016) and, depending on the brain region, consist of 5-
12% of the total cell population in the mouse brain (Lawson et al., 1990). 
Microglia originate from the microglial progenitors of the yolk sac which 
migrate to the brain during early embryonic development and proliferate in 
the brain to form the adult microglia population (Alliot et al., 1999). It was 
later confirmed that microglia are, indeed, a distinct population from the 
hematopoietic stem cells and a unique group of tissue macrophages that are 
independently maintained in the brain throughout life (Ginhoux et al., 2010; 
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Schulz et al., 2012; Kierdorf et al., 2013). In contrast, peripheral immune cells 
are derived from the hematopoietic stem cells of the bone marrow and are 
constantly renewed. Despite different origins, monocyte-derived macrophages 
and microglia express the same genes and proteins, therefore making it 
challenging to reliably distinguish microglia from bone marrow-derived 
macrophages. Only recently have novel techniques using gene-modified 
fluorescent reporter mice, chimeras, or fluorescent cell transfer, and the 
discovery of specific microglia markers (transmembrane protein 119; 
TMEM119) enabled identification between microglia and monocyte-derived 
macrophages. 
Figure 3. A simplified categorization of the role of major myeloid cell types (microglia, 
monocytes/macrophages, neutrophils) and lymphocytes in acute ischemic stroke. An
overall beneficial role of each cell type in stroke is indicated with green color and a
detrimental role with red color. Lymphocytes, neutrophils, and monocytes derive from 
hematopoietic stem cells of the bone marrow while microglia derive from microglia 
progenitors of the yolk sac. Monocytes differentiate into macrophages after migration
to tissues. Of lymphocytes, regulatory B (BReg) and T cells (TReg) have beneficial roles 
in ischemic stroke, whereas other cell types are considered more harmful. Neutrophils 
are considered mainly damaging, whereas there is increasing evidence of the 
beneficial role of monocyte-derived macrophages. Microglia have a complex role with 
both detrimental and regenerative functions. Macrophages and microglia have an
important role in debris removal after ischemia-induced cell death.  
NK, natural killer
2.2.1 PERIPHERAL RESPONSES
 
The peripheral immune system has a prominent role in the post-stroke 
inflammatory response and stroke pathogenesis. The peripheral inflammatory 
response to ischemia is induced instantly in the vascular endothelium and 
platelets by the release of adhesion molecules which attract blood leukocytes 
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to the endothelial surface at the infarct site and can cause further blockage of 
blood flow when clustered. Also, thrombin, the activated blood-coagulation 
factor residing in the ischemia-inducing blood clot, causes chemotaxis, and 
other proteases of the coagulation cascade can activate the innate immunity 
complement system. Activation of the complement system has been linked 
with worse outcomes in ischemic stroke patients (Szeplaki et al., 2009). BBB 
disruption leads to leukocyte infiltration into the brain parenchyma and 
conversely, to leakage of cytokines and other inflammatory mediators into the 
systemic circulation. Also, other blood components enter the brain causing 
water uptake by osmosis and edema. Monocytes are the major infiltrating cell 
type (see in chapter 2.2.3) and the relative amount of other leukocytes is 
significantly smaller.  
Inflammatory cytokines increase within a few hours after ischemia-
reperfusion injury in mouse blood, spleen, lung, and liver (Offner et al., 2006a; 
Chapman et al., 2009). In ischemic stroke patients, elevated plasma C-reactive 
protein (CRP) and cortisol levels and white blood cell count have already been 
found at admission to the hospital and increased interleukin-6 (IL-6) levels by 
24h after symptom onset (Emsley et al., 2003). High plasma levels of IL-6 and 
CRP in acute ischemic stroke have been associated with larger infarcts and 
worse neurological outcome (Fassbender et al., 1994a; Smith et al., 2004; 
Basic Kes et al., 2008), whereas low IL-10 levels were associated with better 
outcomes (Basic Kes et al., 2008).  
After the acute response, ischemic stroke induces depression of the 
peripheral immune system and infections are a common complication in 
stroke patients. Immunosuppression may be caused by the release of 
glucocorticoids and catecholamines after stroke (Fassbender et al., 1994b; 
Chamorro et al., 2007). Decreased spleen size (Sahota et al., 2013; Chiu et al., 
2016), splenic contraction (Vahidy et al., 2016; Zha et al., 2018), and increased 
apoptosis of lymphocytes (Urra et al., 2009) within the first days after stroke 
has been observed in patients. In mice, ischemic stroke induces persistent 
lymphopenia and shrinkage of spleen and thymus caused by increased 
apoptosis of lymphocytes (Prass et al., 2003; Offner et al., 2006b; Bao et al., 
2010). Apoptosis was reversed with a β-adrenergic receptor antagonist and 
may be caused by overactivation of the sympathetic nervous system (Prass et 
al., 2003), or alternatively, nuclear protein high motility group box 1 (HMGB1) 
release from necrotic cells of the infarct to systemic circulation in mice and 
stroke patients has been suggested to cause immunosuppression (Liesz et al., 
2015).  In rats, the primary cause for splenic lymphopenia is a catecholamine-
induced contraction of the spleen and the release of splenocytes into the 
systemic circulation (Ajmo et al., 2009; Seifert et al., 2012), highlighting 
species differences.  
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2.2.2 INFILTRATION OF LYMPHOCYTES AND NEUTROPHILS
 
The spleen is the major source of monocytes and lymphocytes and a 
splenectomy 2 weeks before MCAo decreases infarction size in male (Ajmo et 
al., 2008; Chauhan et al., 2018), but not in female animals, possibly due to sex 
differences in regulatory T cells involved in adaptive immunity (Dotson et al., 
2015). However, in patients, splenectomy has been associated with an 
increased risk for stroke (Lin et al., 2015). CD4+ and CD8+ T cells have a 
deleterious role in acute ischemia-reperfusion injury, and T cell depletion in 
mice reduces infarct size (Yilmaz et al., 2006; Hurn et al., 2007). Also δγ T 
cells exacerbate ischemia-reperfusion injury in mice by producing pro-
inflammatory IL-17 (Shichita et al., 2009). However, regulatory T cells are 
neuroprotective in both permanent and transient MCAo in mice by reducing 
inflammation (Liesz et al., 2009; Li et al., 2013). Also, regulatory B cells have 
shown benefits in experimental acute ischemic stroke and reduced ischemic 
injury in mice by releasing IL-10 (Ren et al., 2011; Bodhankar et al., 2013). In 
patients, low plasma levels of B cells at admission were associated with poor 
outcome at 3 months post-stroke (Urra et al., 2009). However, B cells have 
been shown to contribute to the development of long-term cognitive decline 
after transient MCAo in mice (Doyle et al., 2015). Natural killer cells, also a 
lymphocyte subtype, exacerbate cerebral ischemic-reperfusion injury in mice 
within the first 12h (Gan et al., 2014). 
Whether neutrophils infiltrate into the brain parenchyma after stroke or 
are present only in the cerebral vessels has been under debate (Enzmann et 
al., 2013), but current evidence suggests that neutrophils first accumulate in 
the leptomeninges and perivascular spaces and thereafter also penetrate into 
the brain parenchyma in rodent models of permanent and transient cerebral 
ischemia as well as in ischemic stroke patients (Perez-de-Puig et al., 2015; 
Otxoa-de-Amezaga et al., 2019a). Neutrophil infiltration into the brain 
parenchyma takes place within 24-72h after permanent or transient ischemia 
(Barone et al., 1992; Gelderblom et al., 2009; Otxoa-de-Amezaga et al., 
2019a). Significant amounts of granulocytes were also found in the infarcted 
human brains during the first 1-2 days after stroke (Lindsberg et al., 1996). 
Neutrophils are considered detrimental in ischemic stroke and increase 
neuronal damage in animal models (Connolly et al., 1996; Neumann et al., 
2015) by secreting proteases toxic to neurons and extracellular matrix 
components (Stowe et al., 2009; Allen et al., 2012), NO (Garcia-Bonilla et al., 
2014),  and by physically occluding cerebral capillaries and preventing 
reperfusion (del Zoppo et al., 1991; Mori et al., 1992). However, there is 
evidence that neutrophils can be harnessed for neuroprotection, where 
pharmacologically induced polarization of brain-penetrated neutrophils 
towards regenerative “N2” type reduced ischemic injury (Cuartero et al., 
2013). In ischemic stroke patients, high blood neutrophil and total leukocyte 
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counts within 24h after symptom onset were associated with larger infarct 
volumes (Buck et al., 2008).  
It was recently reported that in infarcted patient post mortem brains only 
a few lymphocytes and neutrophils were found which may suggest that the 
contribution of these cell types is minor in patients compared to experimental 
animals (Zrzavy et al., 2018).  
2.2.3 MICROGLIAL ACTIVATION AND INFILTRATION OF MONOCYTE-
DERIVED MACROPHAGES 
 
Microglia have an important and constant role in maintaining central nervous 
system (CNS) homeostasis: microglia are involved in the development, 
remodeling, function, and plasticity of neuronal networks [see in (Kettenmann 
et al., 2011)]. Microglia express numerous cell surface receptors that 
continuously sense molecular cues for changes in physiological conditions. 
Under pathologic conditions, microglia go through phenotypical changes that 
are regarded as “microglial activation” even though microglia is never inactive. 
These changes involve morphological alterations from stationary, highly 
ramified cells towards motile, amoeboid or round-shaped cells resembling 
peripheral macrophages, acquiring phagocytic function, and production of 
secreted molecules that can be pro-inflammatory [e.g. tumor necrosis factor α 
(TNF-α), IL-1β, IL-6, NO], anti-inflammatory (e.g. IL-10), or pro-regenerative 
[e.g. VEGF, insulin-like growth factor 1 (IGF-1), BDNF, GDNF]. Reactive 
microglia and macrophages were suggested to possess two distinct 
phenotypes, the classic pro-inflammatory/degenerative “M1” phenotype, and 
the alternative anti-inflammatory/regenerative “M2” phenotype. Recent 
evidence from single-cell transcriptomics has proven this classification an 
oversimplification with no relevance to in vivo conditions and microglia as 
well as monocyte-derived macrophages express both “M1” and “M2” markers 
within the same cell [see in (Ransohoff, 2016)]. The environment has been 
considered as the primary factor defining the microglia phenotype. However, 
it was recently suggested that microglia population would consist of different 
subtypes with intrinsic properties that define microglia phenotype, rather than 
solely the tissue environment [see in (Stratoulias et al., 2019)].
In the ischemic brain, microglia respond rapidly to danger-associated 
molecular patterns which are intracellular molecules released from the 
ischemia-injured cells. Microglial activation has already been observed 30 min 
after permanent MCAo induction in the mouse brain (Rupalla et al., 1998). 
However, like neurons, microglia are dependent on ATP and die in the infarct 
core, and thus, microglia are the defining factor for the peri-infarct region. 
Microglial degeneration has been observed 4h after transient MCAo (Kato et 
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al., 1996) and significant microglia loss at 12-72h (Lehrmann et al., 1997; Ito 
et al., 2001; Ritzel et al., 2015). 
The role of microglia in ischemic stroke is conflicting. In the hyperacute 
phase, microglia depletion has been shown to increase lesion size, possibly by 
many mechanisms, including decreased secretion of growth factors, increased 
neuronal excitotoxicity and Ca2+ dysregulation, and increased neutrophil 
infiltration (Lalancette-Hebert et al., 2007; Szalay et al., 2016; Otxoa-de-
Amezaga et al., 2019b). Considering the role of microglia in maintaining CNS 
homeostasis, it is not surprising that the depletion of microglia is detrimental. 
Furthermore, transplantation of exogenous microglia during transient MCAo 
decreased neuronal damage (Kitamura et al., 2004; Narantuya et al., 2010). 
Narantyua et al. characterized the gene expression profile of transplanted 
microglia and found that several growth factors and anti-inflammatory 
cytokines were upregulated after transplantation.  However, there are also 
studies showing that acute inhibition of microglia activation is protective in 
ischemic stroke (Yrjanheikki et al., 1999; Gelosa et al., 2014) but the 
interventions studied are rarely specific for microglia and direct effects on 
other immune cells, glia, and neurons may confound results. 
Unlike microglia, macrophages survive in hypoxic conditions by switching 
to anaerobic metabolism. In experimental stroke models, peripheral 
monocyte-derived macrophages infiltrate the ischemic core peaking between 
3 and 7 days post-stroke (Schroeter et al., 1997; Perego et al., 2011; Gliem et 
al., 2012; Ritzel et al., 2015; Wattananit et al., 2016). In ischemic stroke 
patients, macrophage accumulation in the infarct region has been found 
between days 4.5 and 8.5, with the highest macrophage amount at 17-18 days 
after stroke (Lindsberg et al., 1996). Using chimeric mice, it was shown that at 
day 7 after permanent MCAo, most of the myeloid cells in the infarct core are 
peripheral macrophages and not resident microglia, whereas in the peri-
infarct region there was an equal amount of both (Tanaka et al., 2003). 
However, in transient (30 min) MCAo, more resident microglia than 
infiltrating monocytes were found in the infarct region (Schilling et al., 2003), 
possibly reflecting the difference in the severity of stroke.  
Infiltration of peripheral monocytes to tissues, including the brain, is C-C 
chemokine receptor 2 (CCR2)-dependent (Boring et al., 1997; Kuziel et al., 
1997; Gliem et al., 2012; Wattananit et al., 2016). Traditionally, infiltrating 
monocytes have been considered detrimental in ischemic stroke and to 
enhance inflammation and lesion development. Genetic removal of CCR2 or 
its ligand monocyte chemoattractant protein 1 [MCP-1; a.k.a C-C motif 
chemokine ligand 2 (CCL2)] reduced infarct volumes compared to wild type 
mice (Hughes et al., 2002; Dimitrijevic et al., 2007), whereas a later study with 
a milder infarct found no difference in infarct development despite decreased 
leukocyte infiltration (Schilling et al., 2009). MCP-1 and CCR2 also have other 
functions than direct chemotactic effects and it was postulated that the 
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protective effect was rather a consequence of an altered cytokine profile than 
decreased monocyte infiltration (Hughes et al., 2002; Schilling et al., 2009).  
Microglia, monocytes, and lymphocytes express CX3C chemokine receptor 
1 (CX3CR1) which binds the pro-inflammatory chemokine fractalkine [a.k.a 
CX3C chemokine ligand 1 (CX3CL1)] (Imai et al., 1997; Harrison et al., 1998). 
In the periphery, fractalkine is expressed on the endothelium where it 
functions as an adhesion molecule and chemoattractant for monocytes and 
lymphocytes (Imai et al., 1997). In the brain, fractalkine is expressed primarily 
by neurons and the interaction with CX3CR1 seems to be important for the 
communication between microglia and neurons and the control of microglia 
activation in homeostatic conditions (Harrison et al., 1998; Cardona et al., 
2006). Upon ischemic injury, genetic deletion of CX3CR1 reduced infarct 
volume in mice and improved short-term behavioral recovery after transient 
MCAo (Denes et al., 2008; Fumagalli et al., 2013; Tang et al., 2014). CX3CR1 
deletion was associated with increased anti-inflammatory markers of 
microglia/macrophages, reduced levels of pro-inflammatory cytokines, and 
decreased infiltration of peripheral leukocytes at 72h post-stroke. However, 
the long-term effects of CX3CR1 deletion after ischemic stroke have not been 
comprehensively studied and could yield different results. It has been 
suggested that the CX3CR1-expressing immune cells represent a patrolling, 
homeostasis-maintaining cell population, whereas the CCR2-expressing cells 
are pro-inflammatory (Geissmann et al., 2003). Interestingly, in patients, high 
plasma fractalkine levels were associated with better functional outcome at 6 
months after ischemic stroke and with decreased inflammation (Donohue et 
al., 2012).  
To date, there is a lot of evidence that the accumulation of monocyte-
derived macrophages to the ischemic area is protective and reduces the 
ischemic lesion and long-term behavioral impairment via production of pro-
regenerative and anti-inflammatory molecules (Smirkin et al., 2010; Gliem et 
al., 2012; Perego et al., 2016; Wattananit et al., 2016). However, there are also 
contradicting data showing reduced ischemic injury after depletion of 
peripheral monocytes (Ma et al., 2016). The varying results could be explained 
by a different method of monocyte depletion, model, and time point of 
analysis. It was suggested that microglia/macrophages first acquire a 
neuroprotective phenotype which is then switched to a neurodegenerative 
phenotype during the first week after ischemic stroke (Perego et al., 2011; Hu 
et al., 2012). However, in ischemic stroke patients, pro-inflammatory markers 
were found to dominate in the acute phase, while anti-inflammatory markers 
were expressed later during infarct resolution (Zrzavy et al., 2018), indicating 
that clinical findings may not correlate with the animal models. Nevertheless, 
there is increasing evidence from recent animal studies that pro-inflammatory 
monocytes change phenotype towards anti-inflammatory/repair-promoting 
after infiltration into the injured tissue (Chu et al., 2015; Garcia-Bonilla et al., 
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2016; Miro-Mur et al., 2016) which could imply that the ischemic environment 
drives a neuroprotective phenotype.  
In comparison to microglia, invading monocytes were found to be more 
efficient in phagocytosis at 72h after transient MCAo, indicating that 
monocyte-derived macrophages have a prominent role in the early debris 
clearing (Ritzel et al., 2015). Phagocytic removal of tissue debris from the 
infarcted brain is vital and a prerequisite for the regenerative processes to take 
over. However, phagocytosis of viable neurons, phagoptosis, can occur in the 
ischemic brain when stressed neurons expose cell membrane structures that 
trigger phagocytosis by macrophages and microglia (Neher et al., 2011; Fricker 
et al., 2012; Neher et al., 2013). Phagoptosis can enhance neuronal damage 
and deteriorate behavioral recovery in ischemic stroke (Neher et al., 2013). 
Clearly, our knowledge of microglia function is still limited, and thorough 
investigation into different microglia phenotypes in ischemic stroke may aid 
in elucidating the role of microglia in stroke pathogenesis. Overall, 
immunomodulation to support anti-inflammatory and reparative processes 
and to dampen pro-inflammatory molecules would seem like a potential 
therapeutic goal instead of focusing on specific immune cell types. Our 
understanding of stroke-induced inflammation is further complicated by the 
dual role of cytokines, illustrated by TNF-α which is neuroprotective when in 
membrane-anchored form and neurodestructive when in a soluble form 
(Clausen et al., 2014; Madsen et al., 2016).  
2.2.4 REMOTE SECONDARY DAMAGE AND LONG-TERM MICROGLIAL 
ACTIVATION
 
The amount of activated microglia and macrophages decreases in the ischemic 
core and peri-infarct area within 1-month post-stroke when the necrotic tissue 
debris has been removed. However, post-stroke neuroinflammation is long-
lasting and activated myeloid cells have been found in the brain for up to six 
months after transient cerebral ischemia (Justicia et al., 2008; Thored et al., 
2009; Anttila et al., 2018). Activated microglia were suggested to promote 
neurogenesis in the subventricular zone (SVZ) for months after intraluminal 
MCAo by expressing IGF-1 (Thored et al., 2009). 
Due to connecting projection pathways, focal ischemic stroke also induces 
delayed neuronal damage in regions distal to the infarct (Nagasawa & Kogure, 
1990) occurring 1-2 weeks after the initial ischemic insult in rodents, and 
microglial activation has been shown to precede the neurodegeneration 
(Korematsu et al., 1995; Rupalla et al., 1998; Dihne & Block, 2001). Microglial 
activation in the thalamus has been reported already 2-3 days after permanent 
or transient MCAo (Rupalla et al., 1998; Loos et al., 2003). In a permanent 
MCAo model, the peak microglial activation in the ipsilateral thalamus was 
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observed between 2-4 weeks with consistent thalamic neuronal loss at 4 weeks 
post-stroke (Rupalla et al., 1998). No microglial activation was present 
anymore at 3 months (Rupalla et al., 1998). Another study using a transient 
MCAo model reported only few activated microglia in the ipsilateral thalamus 
at 1 week after the MCAo but large amounts of activated microglia were found 
at 4 weeks post-stroke (van Groen et al., 2005).  This secondary pathology is 
accompanied by β-amyloid and Ca2+ accumulation in the ipsilateral thalamus 
observable from 1 week up to 9 months after transient MCAo in rat (van Groen 
et al., 2005; Makinen et al., 2008), but significant β-amyloid accumulation 
has not been found in the nonhuman primate marmoset nor in ischemic stroke 
patients (Aho et al., 2006; Lipsanen et al., 2013). However, thalamic atrophy 
and microglial activation similar to rodents have been observed in patients 
with middle cerebral artery infarction (Tamura et al., 1991; Pappata et al., 
2000). The role of secondary thalamic neurodegeneration in post-stroke 
functional recovery is unknown but the integrity of thalamic circuitry has been 
implicated in motor recovery of patients (Binkofski et al., 1996). However, a 
study by Thiel et al. found a positive correlation between distal microglial 
activation and better functional outcome in patients with subcortical infarcts 
(Thiel et al., 2010), implying the secondary inflammation may have beneficial 
effects on recovery. 
2.2.5 ASTROCYTES 
 
In addition to microglia, astrocytes are an important regulator of CNS 
homeostasis and the most abundant cell type in the brain [see in (Sofroniew, 
2009; Liu & Chopp, 2016; Pekny et al., 2016; Iadecola, 2017)]. Astrocytes 
regulate synaptic plasticity and synaptogenesis, ion and neurotransmitter 
homeostasis, provide metabolic support for neurons, and are an essential part 
of the neurovascular unit regulating cerebral blood flow to meet the needs of 
neuronal activity.  
Upon injury, the branched astrocytes become rapidly reactive, involving 
changes in gene expression, cell hypertrophy, and in severe cases proliferation 
and permanent scar formation around the injury (Sofroniew, 2009). The 
astrocytic scar is considered an attempt to limit tissue injury and inflammation 
as it forms a physical barrier between the injured and healthy tissue. In a 
photothrombotic stroke model, reactive astrogliosis was shown to promote 
behavioral recovery in wild type mice when compared to genetically modified 
mice with reduced astrocytic scar formation (Liu et al., 2014). Also in other 
disease models, attenuated scar formation has led to a worse outcome, 
including increased inflammation, tissue damage, and lesion size (Sofroniew, 
2009). Moreover, reactive astrocytes can limit excitotoxicity by uptake of 
excess extracellular glutamate, increasing BBB repair, and decreasing 
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vasogenic edema after cerebral injury (Bush et al., 1999), as well as decrease 
of oxidative stress (Chen et al., 2001b). However, as for microglia, there is also 
evidence that decreasing reactive astrogliosis is neuroprotective in 
experimental ischemic stroke (Adelson et al., 2012). Under some 
circumstances not well known, reactive astrocytes can exacerbate injury via 
pro-inflammatory cytokine and ROS production, glutamate release, and 
increased edema formation (Sofroniew, 2009). 
Reactive astrocytes also regulate innate immunity by expressing innate 
immunity receptors, such as Toll-like receptors, and by producing cytokines 
and chemokines [see in (Farina et al., 2007)]. Reactive astrocytes control the 
extracellular environment with both degenerative and recovery-promoting 
effects, and can release pro-inflammatory molecules (e.g. TNF-α, IL-6, IL-1β) 
especially in the acute phase of stroke but also produce anti-inflammatory [e.g. 
transforming growth factor β (TGF-β)] and neurotrophic [e.g. BDNF, nerve 
growth factor (NGF), GDNF, ciliary neurotrophic factor (CNTF), VEGF] 
molecules (Liu & Chopp, 2016).  
Collectively, astrocytes have a complex role in post-stroke 
neuroinflammation and recovery. In addition to possible detrimental effects, 
astrocytes are involved in multiple brain repair mechanisms after stroke, 
including neurogenesis, synaptogenesis, angiogenesis, and axonal 
remodeling. However, many functions of astrocytes remain still unexplored. 
Interest in astrocyte-targeted stroke therapies has truly started to emerge only 
during the last decade and is expected to increase as the knowledge on 
astrocytes’ role in ischemic stroke recovery will be further clarified. 
2.3 NALOXONE
(-)-Naloxone is a μ, δ, and κ opioid receptor antagonist and is clinically used 
for the treatment of opioid overdose (Iijima et al., 1978). The (+) enantiomer 
of naloxone needs to be synthesized separately and has a very low affinity for 
opioid receptors — approximately 10,000 times less than the (-) enantiomer 
(Iijima et al., 1978). Numerous clinical trials in stroke patients have been 
conducted on the acute effects of (-)-naloxone after the first report in 1981 on 
the ability of naloxone to transiently reverse neurological deficits in patients 
with cerebral ischemia (Table 1). Unfortunately, all of these trials were 
designed based on the assumption of the beneficial effects of opioid receptor 
antagonism in acute ischemic stroke, and the larger patient studies were 
finally negative (Federico et al., 1991). However, in vitro studies (Table 2) with 
(-)-naloxone later in the 1990s hinted that it may have anti-inflammatory 
effects independent from opioid receptors (Das et al., 1995; Kong et al., 1997). 
Still in the 21st century, the in vivo experiments in ischemic stroke models were 
focused on the acute effects of naloxone (Table 3) and pretreatment with (+)-
naloxone was shown to be ineffective in limiting the lesion volume, whereas (-
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)-naloxone was effective and the protection was associated with μ opioid 
receptor antagonism (Liao et al., 2003). 
The conclusion of the various clinical studies of acute (-)-naloxone seems 
to be that (-)-naloxone may be able to transiently reverse neurological deficits 
when given very early in a mild, transient ischemic attack. The acute treatment 
does not seem to have an effect on the long-term outcome of ischemic stroke. 
It has been postulated that acute (-)-naloxone treatment would reverse 
neurological deficits only in the patients who would eventually recover 
spontaneously (Hans et al., 1992). Also, care should be taken when 
interpreting the results of open-label trials as (-)-naloxone showed no 
significant effects in any of the double-blinded studies. 
Table 1. Clinical trials conducted with (-)-naloxone in patients with cerebral ischemia.
Time of treatment refers to time passed from symptom onset.
Time of 
treatment
Dose Outcome Reference
Several days 0.4 mg i.v. x 3-8 in 24h-
48h
Reversal of 
neurological deficits 
in 2/2 patients
(Baskin & 
Hosobuchi, 1981)
First hours 25.2 mg in 30 min Reversal of 
neurological deficits 
in 2/5 patients
(Perey et al., 1984)
≤3-24h 0.8-1.2 mg i.v. x 2-3 in 10 
min intervals
Reversal of 
neurological deficits 
3/13 patients
(Jabaily & Davis, 
1984)
≤24h 0.4 mg x 3 i.v. in 5 min 
intervals 
No effect (n=40) (Perraro et al., 1984)
≤8-60h 0.4-4 mg x 2 i.v. in 1h 
intervals
No effect (n=15) (Fallis et al., 1984)
5h-8d 0.4 mg i.v. in 30 min Reversal of 
neurological deficits 
in 4/11 patients
(Bussone et al.,
1985)
3 groups:
<10 min;
<24h;
7-14d
0.8 mg i.v. Reversal of 
neurological deficits 
in 3/3 patients 
(<10min); 7/20 
(<24h); no effect (7-
14d)
(Estanol et al., 1985)
<48h 52.3-4 978 mg/24h Reversal of 
neurological deficits 
in 13/27 patients
(Adams et al., 1986)
≤48h 4 mg/kg/15 min i.v. 
loading dose + 2 mg/kg/h 
for 24 h
No effect (n=38) (Olinger et al., 1990)
≤12h 5 mg/kg/10 min i.v. 
loading dose + 3.5 
mg/kg/h for 24h
No effect (n=24) (Federico et al.,
1991)
i.v., intravenous
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Table 2. In vitro effects of naloxone in neurodegeneration and inflammation.
Enantiomer Model Effect Reference
LPS
(-) LPS-treated primary 
neuron-glia cultures
IL-1β ↓
Microglial activation ↓
(Das et al., 1995)
(-) LPS-treated primary 
glial cultures
NO; TNF-α  ↓ (Kong et al.,
1997)
(+); (-) LPS-treated primary 
neuron-glia cultures
Neuronal loss ↓
NO; TNF-α  ↓
(Liu et al.,
2000b)
(+); (-) LPS-treated primary 
neuron-glia cultures
Neuronal loss ↓
Microglial activation ↓
NO; IL-1β ↓ 
Superoxide production ↓
(Liu et al.,
2000a)
(-) LPS-treated primary 
neuron-glia cultures
Neuronal loss ↓
ROS; superoxide production ↓
(Qin et al., 2005)
(+) LPS-treated HEK-
TLR4 cells
LPS-treated rat 
microglia
TLR4 signaling ↓
CD11b; IL-1β; IL-6 ↓
(Hutchinson et 
al., 2008)
(+); (-) LPS-treated primary 
neuron-glia cultures; 
PMA-treated 
neutrophils
Superoxide production ↓ (Wang et al.,
2012)
(+) LPS-treated 
microglia/ 
macrophages
NO, TNF-α  ↓
Phagocytosis  ↓
NF-κB ↔
IRF3; IFN-β ↓
(Wang et al.,
2016a)
Other
(+); (-) Aβ-treated primary 
neuron-glia cultures
Neuronal loss ↓
Superoxide production ↓
(Liu et al., 2002)
Aβ, β-amyloid peptide; CD11b, cluster of differentiation molecule 11b; HEK, human embryonic 
kidney; IFN-β, interferon β; IL, interleukin; IRF3, interferon regulatory factor 3; LPS,
lipopolysaccharide; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells;
NO, nitric oxide; PMA, phorbol myristate acetate; ROS, reactive oxygen species; TLR4, Toll-
like receptor 4; TNF-α, tumor necrosis factor α
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Table 3. In vivo effects of naloxone in neurodegeneration and inflammation.
Enantiomer Model Dose Effect Reference
Ischemic stroke
(-) 90min 
dMCAo in rat
0.03 mg or 0.3 
mg/4h i.c.v
infusion 1h
before dMCAo
0.3 mg/4h i.c.v. 
infusion 30min 
after occlusion
Infarct volume ↓
Antioxidant activity ↓
Pyruvate ↑
Infarct volume ↓
(Chen et al.,
2000)
(-) 90min 
dMCAo in rat
0.03 mg or 0.3 
mg/4h i.c.v.
infusion 1h
before dMCAo
Infarct volume ↓ 
Neuroinflammation ↓
(Chen et al.,
2001a)
(-)
(+)
90min 
dMCAo in rat
82.5 nmol/4h
i.c.v. infusion 1h 
before dMCAo
Infarct volume ↓
Neutrophil infiltration ↓
Infarct volume ↔
(Liao et al.,
2003)
Parkinson’s disease
(+); (-) Intranigral 
LPS in rat
1 mg/day s.c. 
infusion for 6d 
24h before LPS
Neuronal loss ↓
Microglial activation ↓
(Liu et al.,
2000c)
Neuropathic pain
(+); (-) Intrathecal 
LPS injection 
in mice
10 ng i.t. 10min 
before LPS
LPS-induced 
antianalgesia against 
morphine ↓
(Wu et al.,
2006)
(+); (-) CCI in rat 20-60 μg/h i.t. 
infusion 10-14d 
after CCI
Neuropathic pain ↓
CD11b ↓
GFAP ↔
(Hutchinson
et al., 2008)
CCI, sciatic nerve chronic constriction injury; CD11b, cluster of differentiation molecule 11b;
dMCAO, distal middle cerebral artery occlusion; GFAP, glial fibrillary acidic protein; i.c.v.,
intracerebroventricular; i.t., intrathecal; LPS, lipopolysaccharide; s.c., subcutaneous
 
To date, a lot of interest has emerged towards the non-stereospecific anti-
inflammatory effects of naloxone enantiomers. It has been proposed that 
naloxone inhibits Toll-like receptor 4 (TLR4) signaling (Hutchinson et al., 
2008; Wang et al., 2016a) by binding to the TLR4 co-receptor MD2 (myeloid 
differentiation factor 2) and leading to inactivation of the receptor 
(Hutchinson et al., 2012; Shah et al., 2016). Activation of TLR4 leads to the 
production of pro-inflammatory cytokines and interferons via signaling 
cascades inducing nuclear translocation of transcription factors NF-κB and 
interferon regulatory factor 3 (IRF3) [see in (Wang et al., 2013)]. TLR4 is 
expressed in innate immune cells, glial cells, and neurons, and genetic removal 
of TLR4 has been shown to protect from cerebral ischemic injury (Cao et al., 
2007; Caso et al., 2007; Tang et al., 2007; Kilic et al., 2008). However, other 
laboratories have failed to replicate the naloxone-induced TLR4 inhibition and 
the effects of naloxone on TLR4 remain obscure (Skolnick et al., 2014). 
Naloxone enantiomers have also been shown to inhibit superoxide 
production in several studies (Liu et al., 2000a; Liu et al., 2002; Qin et al., 
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2005; Wang et al., 2012). The neuroprotective and anti-inflammatory effect of 
naloxone against lipopolysaccharide (LPS) was lost in the primary cultures of 
PHOX-/- knockout (ko) mice lacking the catalytic subunit 91 kDa glycoprotein 
(gp91phox) of NADPH oxidase 2 (NOX2), the ROS-producing enzyme, 
indicating that functional NOX2 is needed for the neuroprotective effect (Qin 
et al., 2005). Wang et al. showed more specifically that both naloxone 
enantiomers are able to directly interact with the gp91phox subunit leading to 
inactivation of NOX2 and reduced superoxide production (Wang et al., 2012). 
NOX2 is abundantly expressed in microglia and NOX2-mediated ROS 
production is increased upon microglia activation [see in (Haslund-Vinding et 
al., 2017)]. Neurons also express NOX2, although to a lesser extent, and may 
contribute to ROS production in pathophysiological conditions. NOX2 
expression is increased after cerebral ischemic injury and shown to exacerbate 
ischemic damage [see in (Kahles & Brandes, 2013)]. Thus, naloxone-induced 
NOX2 inhibition could be a potential therapeutic approach in ischemic stroke.  
Both naloxone enantiomers decrease microglial activation in vivo in the rat 
CNS (Liu et al., 2000c; Hutchinson et al., 2008). Therefore, the 
immunomodulatory effects of naloxone could be harnessed for potential 
stroke therapy but would require treatment during the post-stroke 
inflammation. Notably, naloxone penetrates the BBB and has favorable 
pharmacokinetic properties for treating CNS diseases (Suzuki et al., 2010). 
However, naloxone has a short half-life of 1-2h depending on the route of 
administration (Krieter et al., 2016), and therefore requires frequent dosing. 
Now that the non-opioid receptor-dependent effects have been revealed, 
naloxone’s full potential in the treatment of ischemic stroke should be 
explored. 
2.4 CDNF/MANF FAMILY OF PROTEINS: FOCUS ON 
MANF
Cerebral dopamine neurotrophic factor (CDNF) and MANF form the 
CDNF/MANF family of proteins. Despite their nomenclature as neurotrophic 
factors, CDNF and MANF are mostly intracellular proteins located in the ER 
lumen. The MANF gene was first identified in renal cell carcinoma patients in 
the 1990s (Shridhar et al., 1996), but the presumed mutations were soon 
verified as normal polymorphism also found in control cases without cancer 
(Evron et al., 1997). MANF protein, historically also called arginine-rich 
protein (ARP), based on the many arginines in the human gene amino (N)-
terminus which however, turned out not to be translated, or arginine-rich, 
mutated in early stage of tumors (ARMET), was first discovered in the early 
2000s when it was initially isolated from a rat mesencephalic astrocyte cell 
line and renamed as MANF (Petrova et al., 2003). MANF is evolutionarily 
conserved and in addition to vertebrates, MANF homologs have been 
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identified in invertebrates as well, e.g. in fruit fly Drosophila melanogaster 
(DmMANF), aphid Acyrthosiphon pisum (Armet), marine sponge Suberites 
domuncula (SDMANF), and nematode Caenorhabditis elegans (Manf-1) 
(Petrova et al., 2003; Palgi et al., 2009; Wang et al., 2015; Sereno et al., 2017; 
Bai et al., 2018). Shortly after, CDNF protein was discovered and shares 59% 
amino acid identity with MANF (Lindholm et al., 2007). CDNF is expressed 
only in vertebrates and its expression levels are much lower than that of 
MANF, for example in human sera, CDNF protein levels are 170 times lower 
than MANF levels (Galli et al., 2019a). To date, MANF is known to be involved 
in various functions of cellular homeostasis and to have cytoprotective effects 
in several cell types. 
2.4.1 FROM STRUCTURE TO FUNCTION
 
MANF is an 18 kDa protein (Mizobuchi et al., 2007) with two main structural 
domains, the N-terminal and carboxy (C)-terminal domain, which are 
connected with a linker (Hellman et al., 2011). In its structure, MANF has 
three parts that seem to be particularly important for its function: the N-
terminal signal peptide, the cysteine bridge (CXXC motif) in the C-terminal 
domain, and the ER retention signal RTDL at the end of the C-terminus, 
making MANF not a classical secretory protein (Figure 4).  
The N-terminal domain of MANF is saposin-like and predicted to bind 
lipids and membranes (Parkash et al., 2009). In the N-terminus, MANF has a 
21 amino acid long hydrophobic signal sequence that translocates MANF 
precursor protein to the ER where this signal peptide is cleaved off to form 
mature MANF protein (Mizobuchi et al., 2007) (Figure 4). Mature MANF is 
localized in the ER lumen and not in the ER membrane (Mizobuchi et al., 
2007). Proteins are translated in ribosomes in the cytosol or outer membrane 
of the ER. Secretory proteins, approximately one-third of all translated 
proteins, are directed into the ER lumen by the signal peptide that allows ER 
translocation via a translocon channel [see in (Braakman & Bulleid, 2011)]. 
Translocation to the ER lumen enables correct protein folding and 
modifications needed in the extracellular environment and is followed by 
transportation of the mature proteins to Golgi for secretion or to membranes. 
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Figure 4. A simplified view of MANF’s structure and possible interactions in the ER 
and Golgi. MANF is directed to the ER by its signal peptide via the translocon channel. 
The signal peptide is cleaved off to form mature MANF protein which resides in the 
ER luminal space (Mizobuchi et al., 2007). It has been proposed that MANF is held 
in the ER lumen via complex formation with the chaperone GRP78 and Ca2+
(Glembotski et al., 2012). MANF is released from the ER upon ER Ca2+ depletion. 
Also KDEL receptors can retain MANF in the ER by binding the RTDL sequence 
(Henderson et al., 2013). KDEL receptors mediate MANF trafficking between the ER 
and Golgi (Mizobuchi et al., 2007; Glembotski et al., 2012; Henderson et al., 2013).
From Golgi, MANF can be either retrieved back to the ER lumen or secreted into the 
extracellular space. Approximate Ca2+ concentrations in the ER lumen, cytosol, and 
extracellular space are indicated.  
CXXC, two cysteines separated by two other residues; ER, endoplasmic reticulum; GRP78, 
78 kDa glucose-regulated protein; KDEL, canonical ER retention signal; RTDL, KDEL-like 
sequence
 
The C-terminus of MANF contains an important cysteine bridge that links 
two helices together (Mizobuchi et al., 2007), and this so-called CXXC motif 
is needed for both the intracellular and extracellular activity of MANF in 
mouse primary neuronal cultures as well as in rat in vivo model of ischemic 
stroke (Matlik et al., 2015). Further indicating the significance of the motif, 
the MANF homolog DmMANF in D. melanogaster is inactive without the 
CXXC motif (Lindstrom et al., 2013). MANF was predicted to have 
oxidoreductase activity since the CXXC motif is a common structure in 
oxidoreductases but so far there is no evidence for such function (Mizobuchi 
et al., 2007; Matlik et al., 2015). Instead, the CXXC motif may be important 
for achieving the correct conformation of the protein structure (Matlik et al., 
2015).   
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Unlike trophic factors, the C-terminus of MANF contains a 4 amino acid 
long ER retention signal, RTDL, resembling the canonical ER retention signal 
KDEL which binds to the KDEL receptors in the ER and Golgi (Mizobuchi et 
al., 2007; Glembotski et al., 2012; Henderson et al., 2013). This retrieval 
sequence mediates the relocation of MANF from Golgi to the ER lumen. MANF 
can also be transported to the Golgi for secretion (Apostolou et al., 2008).   
The MANF gene was found to be related to the UPR (Lee et al., 2003) which 
occurs as a protective mechanism against the accumulation of unfolded 
proteins within the ER lumen a.k.a. ER stress. MANF mRNA and protein levels 
are upregulated by ER stress via the ER stress response element II (ERSE-II) 
in the Manf promoter region (Mizobuchi et al., 2007; Apostolou et al., 2008; 
Tadimalla et al., 2008). The ER lumen is responsible for the correct folding 
and post-translational modifications of newly synthesized secreted and 
membrane proteins [see in (Walter & Ron, 2011)]. Disturbances in ER function 
lead to the accumulation of unfolded and misfolded proteins in the ER lumen 
and trigger the UPR which is regulated by three main pathways: PERK 
(double-stranded RNA-activated protein kinase-like ER kinase), IRE1 
(inositol requiring enzyme 1) and ATF6 (activating transcription factor 6). 
When activated, these pathways reduce the ER protein load by regulating 
proteolysis, translation, and mRNA degradation in the ER. Despite UPR being 
a cytoprotective mechanism, it can lead to apoptosis if ER stress is prolonged, 
particularly in cells that are secreting substantial amounts of proteins. 
However, it is not well known whether prolonged ER stress plays a role in 
neurodegeneration. 
Endogenous MANF is secreted from cultured cells as it can be detected in 
the cell culture medium, and the secretion is highly enhanced by ER Ca2+ 
depletion but not other types of ER stress (Petrova et al., 2003; Apostolou et 
al., 2008; Tadimalla et al., 2008; Glembotski et al., 2012). It has been shown 
that removal of the RTDL sequence increases MANF secretion from neuronal 
and non-neuronal cells in basal conditions (Glembotski et al., 2012; Oh-Hashi 
et al., 2012; Henderson et al., 2013). However, overexpression of the ER 
chaperone GRP78 (78 kDa glucose-regulated protein), one of the targets of 
UPR-regulator ATF6, was able to retain MANF in non-neuronal cells even 
when the RTDL sequence was deleted, implying an RTDL-independent 
interaction between MANF and GRP78 (Oh-Hashi et al., 2012). Indeed, 
GRP78 together with Ca2+ was found to form a complex with MANF that 
retains MANF in the ER lumen, and the ER Ca2+ depletion-induced MANF 
secretion was not dependent on the RTDL sequence in non-neuronal cells 
(Glembotski et al., 2012). However, Henderson et al. showed that the RTDL 
sequence was, indeed, needed for ER retention and secretion of proteins in 
response to ER Ca2+ depletion in a neuronal cell line (Henderson et al., 2013). 
These data imply that the regulation of MANF secretion may be cell type-
specific, possibly due to differences in ER structure and KDEL receptor 
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subtypes between cells. Furthermore, it has been implicated that all ER 
luminal proteins containing the ER retention signal are secreted upon ER Ca2+ 
depletion in neuronal cells (Trychta et al., 2018). 
The physiological responses to increased MANF secretion upon ER lumen 
Ca2+ depletion are unknown. Also upon ischemic stroke, ER Ca2+ is depleted, 
releasing MANF to the extracellular space. The released MANF could act as an 
emergency signal for myeloid cells and modulate the phenotype of these cells 
and the recruitment of phagocytic cells to the injury area. These views are 
discussed more in chapter 2.4.4. 
2.4.2 EXPRESSION OF MANF
 
MANF protein is widely expressed in different tissues including the brain 
(Figure 5), and highly expressed particularly in secretory tissues, such as 
pancreas, and in the immune system-related tissues, such as bone marrow, 
lymph node, and spleen in human and mouse (Mizobuchi et al., 2007; 
Lindholm et al., 2008; Uhlen et al., 2015; Danilova et al., 2019b). This is 
logical, as MANF has been shown to have a role in protein folding homeostasis 
(Yan et al., 2019). In the healthy mouse brain, MANF protein is expressed 
mainly in neurons but Manf mRNA levels are also high in astrocytes, 
microglia, oligodendrocytes, and endothelial cells (Lindholm et al., 2008; 
Zhang et al., 2014). MANF protein expression is highest during postnatal 
development on postnatal days 3-6 in mice, decreasing thereafter and is lowest 
in the adult (Wang et al., 2014). Cerebral MANF expression has been observed 
already during early embryonic development, mRNA at embryonic day (E) 
12.5 and protein at E14, in mice (Lindholm et al., 2008). It was recently shown 
that MANF protein expression decreases with age in the fruit fly and mouse 
tissues, and in human serum (Sousa-Victor et al., 2019). Decreased MANF 
expression could predispose for many age-related diseases, such as ischemic 
stroke and Parkinson’s disease. 
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Figure 5. MANF is widely expressed in the brain. A: Sagittal view of the anti-MANF 
immunostained adult rat brain. 40x magnification of the B: cortex, C: thalamus and D:
cerebellum. Scale bar is 1000 μm in A and 50 μm in B-D. Unpublished result.
 
MANF expression is upregulated upon ER stress in vitro (Mizobuchi et al., 
2007; Apostolou et al., 2008) and in vivo after various injuries in different 
tissue and cell types. In the brain, short (10 min) global ischemia transiently 
increased neuronal Manf mRNA levels at 24h in the rat hippocampus 
(Lindholm et al., 2008). Transient focal ischemia increased neuronal MANF 
protein expression at 2-48h post-MCAo in the rat ischemic cortex, especially 
in the peri-infarct region, while expression in the infarct core was low 
(Apostolou et al., 2008; Yu et al., 2010). Interestingly, in the same MCAo 
model, Shen et al. showed that MANF protein is upregulated not only in 
neurons of the ischemic cortex but also in the CD68+ microglia/macrophages 
and in oligodendrocytes at 24h post-stroke (Shen et al., 2012). Minor MANF 
expression was also found in astrocytes in the ischemic cortex but not in the 
non-ischemic brain (Shen et al., 2012). In the CD68+ cells of the ischemic 
cortex, MANF expression colocalized with GRP78 (Shen et al., 2012). Increase 
in MANF protein expression, mainly in neurons, has been recently shown to 
also occur in hemorrhagic stroke models at 3-72h after injury induction (Xu et 
al., 2018; Li et al., 2019). Also, 24h after traumatic brain injury (TBI) both 
protein and Manf mRNA levels were elevated around the cerebral contusion 
in rat and human (Li et al., 2018). However, especially in the TBI samples, the 
quality of the immunostainings could have been improved and, surprisingly, 
only little basal MANF expression was found in the rat and human brain (Li et 
al., 2018). In addition, status epilepticus was shown to increase neuronal Manf 
mRNA levels at 2-24h after seizure in mice (Lindholm et al., 2008), and 
transgenic mice with cerebral β-amyloid deposits had elevated neuronal 
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MANF expression, together with increased GRP78 and C/EBP homologous 
protein (CHOP) expression, at 4-6 months of age (Xu et al., 2019). 
In the heart, permanent myocardial ischemia increased MANF levels in the 
area surrounding the infarct at 4-14 days after the injury (Tadimalla et al., 
2008). Hypoxia increased Manf mRNA and protein levels in rat primary 
retinal ganglion cells 24-48h after hypoxia induction with cobalt chloride (Gao 
et al., 2016). In patients with spleen trauma, MANF protein was expressed 
heavily in the spleen plasma cells that synthesize and secrete large amounts of 
antibodies and some MANF+ cells also expressed markers of the UPR (Liu et 
al., 2015). Plasma cells are differentiated B cells and the ER is known to 
expand upon plasma cell differentiation and is regulated by the UPR pathways 
(Zhu et al., 2019). MANF protein expression was also found in a few 
macrophages and T cells but not in undifferentiated B cells (Liu et al., 2015). 
Despite the high number of MANF expression studies, often proper 
controls verifying the specificity of the antibody have been missing. Also, long-
term studies of cerebral MANF expression after ischemia and in ischemic 
stroke patient samples are lacking, thus leaving our knowledge of endogenous 
MANF expression pattern in ischemia incomplete. 
2.4.3 THERAPEUTIC EFFECTS OF MANF
 
There is a vast amount of evidence that MANF is important for cell 
homeostasis and able to protect neurons and also other cell types from 
injuries. At first, MANF was found to specifically promote the survival of 
dopaminergic neurons (Petrova et al., 2003), but to date it has become clear 
that MANF also has multiple other effects. MANF has been implicated in the 
regulation of ER stress, inflammation, apoptosis, neuronal differentiation and 
migration, as well as energy homeostasis and metabolism (Figure 6). Many of 
MANF’s effects may have not yet been discovered as the putative plasma 
membrane receptor mediating MANF’s effects, if there is such, is still obscure. 
The studies revealing MANF’s role in different disease models are summarized 
in table 4. 
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Figure 6. Potential therapeutic targets of MANF.  
ER, endoplasmic reticulum
 
Effects of intracellular MANF 
Intracranial delivery of Manf cDNA via viral vector before ischemic stroke 
induction protects from the injury (Airavaara et al., 2010) and more 
importantly, post-stroke delivery of Manf cDNA 2 days after ischemic stroke 
promotes functional recovery (Matlik et al., 2018). Furthermore, endogenous 
neuronal Manf was shown to protect from permanent ischemia using 
NestinCre/+::Manfflox/flox(fl/fl) mice with conditional deletion of Manf from 
neural lineage cells (Matlik et al., 2018). Endogenous Manf has also been 
shown to be important for neuronal differentiation and migration during 
mouse cortical development (Tseng et al., 2017). 
In several organisms, MANF has been shown to be important for either the 
development or maintenance of dopaminergic neurons. In D. melanogaster, 
the Manf homolog DmManf is needed for the maintenance of dopaminergic 
neurites and survival of dopaminergic neurons, and full deletion of DmManf 
is embryonically lethal (Palgi et al., 2009). In the DmManf deficient embryos, 
genes related to ER stress were upregulated and metabolism-related genes 
downregulated (Palgi et al., 2012). In zebrafish, knockdown of Manf during 
development leads to a reduced number of dopaminergic neurons (Chen et al., 
2012). In C. elegans, removal of the Manf homolog Manf-1 induces ER stress 
and degeneration of dopaminergic neurons with aging (Richman et al., 2018), 
but in young adults, Manf-1 does not seem to be needed for dopaminergic 
neurons’ survival (Hartman et al., 2019). Intracellular overexpression of Manf 
via an adeno-associated viral (AAV) vector protects the dopaminergic cell 
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bodies of substantia nigra and is able to regenerate the tyrosine hydroxylase-
positive fibers in the striatum in the 6-hydroxydopamine (6-OHDA)  model of 
Parkinson’s disease even when AAV-MANF is injected into the striatum 10 
days after the toxin (Hao et al., 2017). Intracellular overexpression of MANF 
also protects the SH-SY5Y neuroblastoma cell line from 6-OHDA-induced 
apoptosis and ER stress in vitro (Hao et al., 2017). Interestingly, MANF 
protein levels were recently found to be increased in Parkinson’s disease 
patients’ sera (Galli et al., 2019a).  
In the pancreas, MANF is needed for the survival and maintenance of β 
cells and removal of Manf from mouse β cells results in diabetes (Lindahl et 
al., 2014; Danilova et al., 2019a). Without Manf the β cells die due to increased 
ER stress and apoptosis and decreased proliferation (Lindahl et al., 2014; 
Danilova et al., 2019a). Viral delivery of Manf cDNA protects mouse 
pancreatic β cells from streptozotocin-induced cell death and enhances β cell 
proliferation in vivo compared to mice injected with red fluorescent protein 
cDNA (Lindahl et al., 2014). In humans, MANF protein levels have been 
shown to be increased in the serum of newly diagnosed diabetic patients (Galli 
et al., 2016; Wu et al., 2017).  
As an indication of the widespread physiological role of MANF, it was 
shown that hypothalamic MANF is involved in the regulation of food intake 
and body weight in mice, and intracellular MANF may have a role in insulin 
signaling by regulating an ER-localized kinase PIP4k2b (phosphatidylinositol 
5-phosphate 4-kinase type-2 beta) (Yang et al., 2017). Overexpression of 
MANF in the mouse hypothalamus increased food intake and body weight, 
whereas removal of Manf from the hypothalamus had the opposite effect 
(Yang et al., 2017). Furthermore, fasting increased MANF protein and gene 
expression in the mouse hypothalamus (Yang et al., 2017). MANF protein 
levels were also elevated in the liver of obese mice after diet change and weight 
loss (Galli et al., 2019b). In humans, fasting was recently found to increase 
MANF protein concentrations in plasma, and the increased circulating MANF 
may originate at least partly from the liver (Galli et al., 2019b). In both humans 
and mice, serum levels of metabolism-regulating hormone adiponectin were 
negatively correlated with MANF levels, indicating a possible role for MANF 
in metabolic homeostasis (Galli et al., 2019b). Interestingly, a recent study 
showed that overexpression of MANF increases the lifespan of D. 
melanogaster and that MANF is able to reverse age-related liver damage in 
mice (Sousa-Victor et al., 2019). MANF deficiency caused changes in lipid 
metabolism and lipid accumulation in the mouse liver which could be reversed 
with MANF overexpression. Increasing MANF by overexpression, or a protein 
injection, also improved glucose and insulin tolerance in old mice.  
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Effects of extracellularly applied MANF 
Overall, recombinant MANF protein is neuroprotective in cerebral ischemia-
reperfusion injury when it is injected intracranially before or a few hours after 
stroke (Airavaara et al., 2009; Yang et al., 2014; Wang et al., 2016b). Also, 
post-stroke infusion of recombinant MANF protein to the peri-infarct area 3 
days after ischemic stroke promotes functional recovery (Matlik et al., 2018)
and even a single intracranial MANF injection 7 days post-stroke is able to 
alleviate neurological deficits (Anttila et al., 2019). In vitro, recombinant 
MANF protein was able to rescue Manf ko mouse primary neuronal stem cells 
from oxygen-glucose deprivation-induced apoptosis (Tseng et al., 2018). 
Moreover, after cerebral ischemia in rats, exogenous MANF infusion increased 
the migration of neural progenitor cells into the infarct region (Tseng et al., 
2018). Additionally, recombinant MANF protein protected rats from 
hemorrhagic stroke (Xu et al., 2018; Li et al., 2019) and TBI (Li et al., 2018). 
In the 6-OHDA model of Parkinson’s disease, recombinant MANF protects the 
dopaminergic cell bodies of the substantia nigra (Voutilainen et al., 2009; Hao 
et al., 2017). Recombinant MANF also protects the SH-SY5Y neuroblastoma 
cell line from 6-OHDA-induced apoptosis in vitro (Huang et al., 2016; Hao et 
al., 2017; Sun et al., 2017; Zhang et al., 2017). Notably, in the study by Hao et 
al. extracellularly applied MANF protein had no effect on UPR markers 
whereas intracellular overexpression of MANF decreased UPR markers in the 
6-OHDA-treated SH-SY5Y cells (Hao et al., 2017). 
The cytoprotective effects of MANF are not limited to neuronal cells but 
recombinant MANF protein also protects rat primary myocardial cells from 
serum starvation-induced apoptosis in vitro (Tadimalla et al., 2008) and 
mouse myocardial cells from ischemia-reperfusion injury in vivo (Glembotski 
et al., 2012). Also in rat retinal ganglion cells recombinant MANF reduced 
hypoxia-induced apoptosis in vivo and in vitro (Gao et al., 2017) and 
decreased photoreceptor loss (Lu et al., 2018), as well as apoptosis in genetic 
mouse models of retinal degeneration (Neves et al., 2016). In mouse primary 
podocytes, a kidney cell population, recombinant MANF was found to 
decrease ER stress-induced cytosolic Ca2+ levels by stabilizing the function of 
the ryanodine receptor channel in the ER and to reduce apoptosis (Park et al., 
2019).  
As discussed, extracellularly applied MANF has shown cytoprotective 
effects both in vivo and in vitro.  However, the mechanism of how extracellular 
MANF exerts its effects in the cell is yet unknown. Based on studies in primary 
cortical neurons, KDEL receptors were proposed to function as cell surface 
receptors for MANF by binding the RTDL motif (Henderson et al., 2013). The 
data was supported by a study on D. melanogaster with knockdown of the 
KDEL receptor homolog in hemocytes, leading to ablation of the 
cytoprotective effect of extracellular MANF and, thus, suggesting KDEL 
receptors are needed for mediating MANF’s effects in hemocytes (Neves et al., 
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2016). However, in the rat ischemic stroke model, the RTDL sequence is not 
needed for the neuroprotective effect which may imply that KDEL receptors 
are not the key receptors at least in the case of cerebral ischemia (Matlik et al., 
2015). More recently, sulphatides were shown to bind extracellular human 
MANF and to mediate its endocytosis in a non-neuronal cell line and were thus 
suggested to function as cell surface receptors (Bai et al., 2018). Furthermore, 
the cytoprotective effect of extracellular MANF was sulphatide-dependent, 
and the sulphatide-bound MANF was able to reduce ER stress in both C. 
elegans and in mammalian cells (Bai et al., 2018). Also, human CDNF protein 
– and green fluorescent protein (GFP) – has been shown to enter the cells via 
endocytosis when injected into the rat brain parenchyma (Matlik et al., 2017). 
However, CDNF does not bind to sulphatides (Bai et al., 2018) and the 
mechanism of endocytosis is likely different for CDNF, perhaps representing 
non-specific uptake since GFP was shown to be similarly taken up by the cells 
(Matlik et al., 2017). 
 
Signaling pathways activated by MANF 
Still, little is known about the signaling pathways MANF may mediate its 
effects with. The Akt (protein kinase B) prosurvival pathway has been 
implicated in some studies. The protective effect of recombinant human 
MANF (rhMANF) protein against 6-OHDA-induced apoptosis in SH-SY5Y 
cells was dependent on activation of the PI3K/Akt/mTOR pathway (Hao et al., 
2017) and against hemorrhagic stroke was suggested to be mediated via 
activation of the Akt/MDM2/p53 pathway (Xu et al., 2018; Li et al., 2019). 
Activation of these pathways leads to enhanced survival and proliferation 
signaling and has been implicated in various cancers (Mundi et al., 2016). 
However, no studies have found any pro-tumorigenic effects by MANF, vice 
versa MANF was recently associated with cancer suppression (Liu et al., 
2019), hinting that MANF may not be a particularly strong Akt activator. In 
neuronal stem cell primary cultures, recombinant MANF, and notably, also 
intracellular overexpression of Manf in neural progenitor cell cultures, was 
shown to activate STAT3 (signal transducer and activator of transcription 3) 
which could mediate MANF’s effects on neuronal differentiation and 
migration (Tseng et al., 2018). In these cells, MANF had no effect on Akt 
activation, indicating it does not function as a classical trophic factor. 
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Table 4. Effects of exogenous MANF therapy (+) and endogenous MANF deletion (-
) in different in vitro and in vivo models.
Model MANF therapy Effect Reference
Apoptosis
Stroke and TBI
Ischemic stroke 
(90min MCAo in rat)
+
(protein)
Infarct volume ↓
Mortality ↓
Neurological function ↑
(Wang et al.,
2016b)
Ischemic stroke 
(60min dMCAo in rat)
+
(protein)
Infarct volume ↓
Apoptosis ↓
Neurological function ↑
(Airavaara et 
al., 2009)
Ischemic stroke 
(60min dMCAo in rat)
+
(AAV)
Infarct volume ↓
Neurological function ↑
(Airavaara et 
al., 2010)
Ischemic stroke 
(120min MCAo in rat)
+
(protein)
Infarct volume ↓
Apoptosis ↓
Neurological function ↑
(Yang et al.,
2014)
OGD in Manf-/- ko 
mouse primary NSCs
+
(protein)
Apoptosis ↓ (Tseng et al.,
2018)
Intracerebral 
hemorrhage in rat
+
(protein)
Apoptosis ↓
Neurological function ↑
Brain edema; BBB leakage ↓
pAkt; pMDM2; Bcl-2 ↑
(Xu et al.,
2018)
Subarachnoid 
hemorrhage in rat
+
(protein)
Apoptosis ↓
Neurological function ↑
Brain edema; BBB leakage ↓
pAkt; pMDM2; Bcl-2 ↑
(Li et al.,
2019)
TBI in rat +
(protein)
Neurological function ↑
Brain edema; BBB leakage ↓
IL-1β; TNF-α; NF-κB ↓
(Li et al.,
2018)
Parkinson’s disease
6-OHDA model in rat +
(protein)
TH+ cell loss in SN ↓ (Voutilainen
et al., 2009)
6-OHDA model in rat +
(AAV)
TH+ cell loss in SN ↓
TH+ fiber loss in STR ↓
(Hao et al.,
2017)
Manf knockdown in 
zebrafish
- TH+ cell number ↓ (Chen et al.,
2012)
6-OHDA-treated 
SH-SY5Y cells
+
(AAV)
+
(protein)
Apoptosis ↓
UPR ↓
Apoptosis ↓
UPR ↔
pAkt; pmTOR ↑
(Hao et al.,
2017)
6-OHDA or α-
synuclein-treated 
SH-SY5Y cells
+
(protein*)
Apoptosis ↓
GRP78; HSP70 ↑
(Huang et al.,
2016; Sun et 
al., 2017)
6-OHDA-treated 
SH-SY5Y cells
+
(protein)
Apoptosis ↓
pmTOR ↑
Mitochondria function ↑
ROS ↓
(Zhang et al.,
2017)
Retina
Light-induced and 
genetic retinal 
damage in mouse
+
(protein)
Apoptosis ↓ (Neves et al.,
2016)
Hypoxia in rat 
primary RGCs
+
(protein)
Apoptosis ↓
CHOP ↓
(Gao et al.,
2017)
Chronic ocular 
hypertension in rat
+
(protein)
Apoptosis ↓ (Gao et al.,
2017)
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Genetic model of 
photoreceptor 
degeneration in rat
+
(protein)
Photoreceptor loss ↓ (Lu et al.,
2018)
Heart
Serum-starved rat 
primary cardiac 
myocytes
+
(protein)
Apoptosis ↓ (Tadimalla et 
al., 2008)
Myocardial ischemia-
reperfusion in mice
+
(protein)
Infarct size ↓ (Glembotski
et al., 2012)
Diabetes
Manf-/- ko mice - β cell death ↑ 
β cell proliferation ↓
(Lindahl et 
al., 2014)
Streptozotocin-
induced diabetes
+
(AAV)
β cell death ↓ 
β cell proliferation ↑
(Lindahl et 
al., 2014)
Other
NGF-deprived mouse 
primary SCG neurons
+
(intracellular
plasmid or 
protein injection)
+
(protein)
Apoptosis ↓
Apoptosis ↔
(Hellman et 
al., 2011)
ER stress
Manf-/- ko mouse - UPR pathways ↑ (Lindahl et 
al., 2014)
Manf knockdown in 
HeLa cells
- Cell proliferation ↑
Cell size ↓
Morphological changes ↑
ER stress-induced apoptosis ↑
UPR pathways ↑
(Apostolou et 
al., 2008)
Overexpression of 
MANF in U2OS cells
+
(LV)
ER stress-induced apoptosis ↓
Cell proliferation ↓
Cell size ↔
(Apostolou et 
al., 2008)
Manf-deficient 
D. melanogaster
- UPR pathways ↑
Lethal
(Palgi et al.,
2012)
Manf-deficient 
C. elegans
- UPR ↑ (Richman et
al., 2018; 
Hartman et
al., 2019)
Aβ-treated SH-SY5Y 
cells
+
(protein* or
plasmid)
UPR ↓
Apoptosis ↓
(Xu et al.,
2019)
ER-stressed mouse 
primary podocytes
+
(protein*)
Ca2+ levels and UPR ↓
Apoptosis ↓
(Park et al.,
2019)
Inflammation
see chapter 2.4.4
Neuronal differentiation and migration 
Manf-/- ko mouse - Neuronal migration ↓
Neurite outgrowth ↓
(Tseng et al.,
2017)
Manf-/- ko mouse 
primary NSCs
- Apoptosis ↔
Neurite outgrowth ↓
Neuronal differentiation ↓
UPR ↑
Protein synthesis ↓
(Tseng et al.,
2017)
Ischemic stroke 
(90min dMCAo in rat)
+
(protein)
Neuronal migration ↑ (Tseng et al.,
2018)
Manf-/- ko mouse 
primary NSCs; 
+
(protein)
Neuronal and glial 
differentiation ↑
(Tseng et al.,
2018)
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SVZ explants (protein / LV) Cell migration ↑
Energy homeostasis and metabolism
Manf-deficient 
D. melanogaster
- Metabolism-related genes ↓ (Palgi et al.,
2012)
Manf knock-in mouse
MANF 
overexpression in 
mouse hypothalamus
MANF knockdown in 
mouse hypothalamus 
+
(transgenic)
+
(AAV)
-
Food intake ↑
Body weight ↑
Food intake ↑
Body weight ↑
Food intake ↓
Body weight ↓
(Yang et al.,
2017)
Manf+/- mouse
Old wt mice
-
+
(protein or 
plasmid)
Lipid metabolism-related 
genes, lipid accumulation in 
the liver ↑
Liver damage ↓
Insulin and glucose tolerance ↑
(Sousa-
Victor et al.,
2019)
6-OHDA, 6-hydroxydopamine; AAV, adeno-associated virus; Aβ, β-amyloid peptide; BBB,
blood-brain barrier; Bcl-2, B cell lymphoma 2; CHOP, C/EBP homologous protein; dMCAo, 
distal middle cerebral artery occlusion; ER, endoplasmic reticulum; GRP78, 78 kDa glucose-
regulated protein; HSP70, 70 kDa heat shock protein; ICH, intracerebral hemorrhage; IL, 
interleukin; ko, knockout; LV, lentivirus; NF-κB, nuclear factor kappa-light-chain-enhancer of 
activated B cells; NGF, nerve growth factor; NSC, neural stem cell; OGD, oxygen-glucose 
deprivation; pAkt, phosphorylated protein kinase B; pMDM2, phosphorylated murine double 
minute 2; pmTOR, phosphorylated mechanistic target of rapamycin; RGCs, retinal ganglion 
cells; ROS, reactive oxygen species; SAH, subarachnoid hemorrhage; SCG, superior cervical 
ganglion; SN, substantia nigra; STR, striatum; SVZ, subventricular zone; TBI, traumatic brain 
injury; TH, tyrosine hydroxylase; TNF-α, tumor necrosis factor α; UPR, unfolded protein 
response; wt, wild type
*NOTE: High concentration of MANF protein used
 
 
Different roles of extracellular and intracellular MANF? 
Collectively, the removal of Manf results in increased ER stress and UPR. 
MANF has been shown to interact with the chaperone GRP78 in the ER 
(Glembotski et al., 2012; Yan et al., 2019). Colocalization of MANF and GRP78 
was already shown by Tadimalla et al. before the direct interaction was known 
(Tadimalla et al., 2008). It was suggested that MANF stabilizes the complexes 
of GRP78 and unfolded proteins in the ER by inhibiting nucleotide exchange 
on GRP78, and thus has a direct role in maintaining ER protein folding 
homeostasis (Yan et al., 2019). Studies with mutated MANF protein have 
revealed that localization to the ER lumen is essential for the anti-apoptotic 
effect of intracellular MANF in mouse primary neuronal cultures (Matlik et al., 
2015). However, the RTDL sequence is not needed for the extracellular activity 
of recombinant MANF protein after parenchymal injection in the rat in vivo 
model of ischemic stroke (Matlik et al., 2015). These data could imply that 
interaction in the ER is necessary for cytoprotection by intracellular MANF, 
whereas the cytoprotective mechanism of extracellular MANF is not mediated 
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by interaction with the ER molecules. Moreover, extracellularly administered 
MANF protein does not protect primary superior cervical ganglion (SCG) 
neurons against apoptosis, but MANF protein injection directly to the 
cytoplasm does (Hellman et al., 2011). Also, MANF does not bind to the 
surface or enter the primary SCG neurons (Hellman et al., 2011). Therefore, 
MANF’s function may depend on the cell type and the plasma membrane 
properties as well since extracellular delivery of MANF protein has been 
shown to protect other cell types in culture (Table 4). There are also some in 
vitro studies showing ER stress-relieving effects with high doses (5 μg/ml – 2 
mg/ml) of recombinant MANF (Park et al., 2019; Xu et al., 2019). Also, 
recombinant MANF at a high dose of 4 μg/ml has shown to upregulate 
chaperone GRP78 and 70 kDa heat shock protein (HSP70) levels while 
protecting a 6-OHDA-stressed neuroblastoma cell line from apoptosis (Huang 
et al., 2016; Sun et al., 2017), pointing out that the UPR also has a protective 
role. In general, MANF has more robust effects in the in vivo settings than in 
cultured cells which may imply that an intact tissue environment is important 
for MANF’s therapeutic actions or that the in vivo therapeutic effect is 
originating from cell types other than neurons. 
In conclusion, the functional role of intracellular and extracellular MANF 
may be different and may depend on the cell type. Intracellular MANF in the 
ER lumen may mainly be a regulator of the ER homeostasis whereas 
extracellular/secreted MANF may have ER-independent functions in various 
pathophysiological conditions. Despite the increasing amount of MANF-
related studies during recent years, the exact mechanism of MANF’s function 
remains unknown. 
2.4.4 IMMUNOMODULATORY EFFECTS OF MANF
 
A rapidly growing amount of evidence from several different model organisms 
indicates that MANF is able to modulate inflammation (Table 5). MANF has 
been shown to downregulate the NF-κB pathway and decrease pro-
inflammatory cytokine production in vitro in several cell types (Zhao et al., 
2013; Chen et al., 2015; Zhu et al., 2016; Cunha et al., 2017; Hakonen et al., 
2018; Liu et al., 2019). Upon activation, the transcription factor NF-κB 
complex translocates from the cytosol to the nucleus where it binds to DNA 
and initiates cytokine transcription. It was suggested that ER stress and 
inflammation would induce MANF translocation to the nucleus, mediated by 
the membrane protein SUMO1 (small ubiquitin-related modifier 1), and allow 
direct interaction with activated NF-κB (Chen et al., 2015; Liu et al., 2019). In 
a mechanistic study using the human embryonic kidney cell line, MANF 
inhibited the binding of NF-κB subunit p65 to the DNA via direct interaction 
of the MANF C-terminal domain and the DNA-binding domain of p65, and 
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thus decreased the gene expression of pro-inflammatory cytokines (Chen et 
al., 2015). Also in the patient liver samples, MANF was shown to colocalize 
with p65 in the nucleus of hepatoma cells and suggested to reduce NF-κB 
signaling and suppress cancer (Liu et al., 2019). However, MANF is typically 
reported to localize in the ER and the prevalence of nuclear localization is 
unknown. 
In D. melanogaster, full deletion of the Manf homolog DmManf induced 
the upregulation of immune and defense response-related genes (Palgi et al., 
2012). In glia-specific DmManf knockdown, a new DmMANF+ microglia-like 
cell type was induced which is interesting since microglia-like cells do not 
normally exist in D. melanogaster (Stratoulias & Heino, 2015). Also in C. 
elegans, the Manf homolog Manf-1 knockdown induced changes in innate 
immunity-related gene expression and reduced growth in the presence of E. 
coli bacteria (Hartman et al., 2019). In marine sponge S. domuncula, the 
MANF homolog SDMANF was shown to colocalize with the Toll-like receptor, 
a receptor important for innate immunity (Sereno et al., 2017). 
In the dMCAo ischemic stroke model, AAV-MANF treatment transiently 
increased the number of phagocytic CD68+ cells and the mRNA levels of 
innate immunity-related genes EGF module-containing mucin-like receptor 1 
(Emr1) and complement component 3 (C3) in the peri-infarct region at post-
stroke day 4 (Matlik et al., 2018). Using proteomics, AAV-MANF was shown 
to downregulate innate immunity proteins, calgranulins A and B (S100A8 and 
S100A9), in the peri-infarct region and the finding was verified with qPCR 
(Teppo et al., 2020). S100A8 and S100A9 form a complex called calprotectin 
complex and have a role in phagocyte recruitment and cytokine production. 
S100A9 was expressed by neutrophils, indicating MANF could regulate 
neutrophil function (Teppo et al., 2020). In a rat model of TBI, MANF 
treatment decreased the levels of pro-inflammatory cytokines around the 
contusion (Li et al., 2018). In light-induced retinal damage in mouse and D. 
melanogaster, MANF increased the number of alternatively activated pro-
regenerative/anti-inflammatory innate immune cells, protected from retinal 
degeneration, and enhanced integration of transplanted photoreceptors 
(Neves et al., 2016). Interestingly, the protective effect of recombinant MANF 
in mouse retina was abolished in CX3CR1 ko mice and MANF failed to induce 
alternative activation in primary macrophage cultures from these mice, 
indicating that CX3CR1 is needed for the MANF-induced cytoprotection and 
immunomodulation (Neves et al., 2016). Similarly, in D. melanogaster, 
hemocyte-specific knockdown of the KDEL receptor abolished MANF’s 
protective and immunomodulatory effect. Hence, at least in the retina of 
mouse and fruit fly, the cytoprotective effect of MANF was suggested to be 
mediated by immune cells. In heterozygous MANF ko mice, inflammation in 
the liver was increased compared to wild type, whereas exogenous MANF 
therapy in old wild type mice decreased liver inflammation (Sousa-Victor et 
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al., 2019). MANF was recently shown to modulate inflammation in the spleen 
as well. In macrophage-specific MANF ko mice, the number of pro-
inflammatory macrophages was increased in the healthy spleen but when 
hepatic fibrosis was induced, the number of alternatively activated spleen 
macrophages increased (Hou et al., 2019). 
In patients, Manf mRNA levels in leukocytes have been shown to be 
elevated in inflammatory diseases rheumatoid arthritis and systemic lupus 
erythematosus (Chen et al., 2015). In addition, immune cell activation after 
ischemic stroke or systemic LPS has been shown to upregulate MANF in 
microglia (Shen et al., 2012; Sousa et al., 2018). 
There is a link between inflammation and ER stress, and activation of the 
IRE1α UPR pathway, and possibly other UPR pathways as well, can activate 
NF-κB [see in (Chaudhari et al., 2014)]. It is thus plausible that MANF could 
downregulate NF-κB and the downstream cytokine production indirectly by 
downregulating IRE1α and other UPR pathways. However, it has also been 
proposed that MANF affects the immune cells in an autocrine/paracrine 
manner thus inducing a phenotypic shift towards reparative functions (Neves 
et al., 2016). Collectively, MANF has immunomodulatory effects which may 
be important for the therapeutic function of MANF in different disease 
conditions. We hypothesize that when MANF is released from injured cells 
upon ER Ca2+ depletion, the released MANF could modulate the immune cell 
phenotype and recruitment of phagocytic cells to the injury area. 
 
Table 5. Implications for immunomodulatory effects by MANF.
Model MANF 
therapy
Effect Reference
Ischemia
OGD in primary rat 
astrocytes
+
(protein)
IL-1β, IL-6, TNF-α ↓
GRP78, NF-κB p65 ↓
(Zhao et al.,
2013)
MCAo in rat - MANF ↑ in 
microglia/macrophages
(Shen et al.,
2012)
dMCAo in rat +
(AAV)
Number of phagocytic cells ↑
Emr1; C3 ↑
(Matlik et al.,
2018)
dMCAo in rat +
(AAV)
S100A8; S100A9 ↓ (Teppo et al.,
2020)
Other tissue damage
Light-induced retinal 
damage in 
D. melanogaster
and mouse
+
(protein)
Alternative activation of innate 
immune cells ↑
(Neves et al.,
2016)
TBI in rat +
(protein)
IL-1β; TNF-α; NF-κB ↓ (Li et al., 2018)
Old wt mouse +
(protein or 
plasmid)
Liver inflammation and damage ↓ (Sousa-Victor
et al., 2019)
Liver cancer in human Colocalization with NF-κB subunit 
p65
Low MANF levels associated with 
poor survival
(Liu et al.,
2019)
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Inflammation
TNF-α-induced 293T 
cells
LPS-induced rat 
primary FLS 
+
(plasmid)
+
(protein)
NF-κB ↓
IL-1β, TNF-α ↓
(Chen et al.,
2015)
Cytokine-induced 
damage in human β 
cells
+
(protein)
Apoptosis ↓
NF-κB pathway ↓
UPR ↓
(Cunha et al.,
2017; 
Hakonen et 
al., 2018)
LPS-injected mice Manf ↑ in microglia (Sousa et al.,
2018)
Manf removal
Manf-deficient 
D. melanogaster
- Immune and defense response-
related genes ↑
(Palgi et al.,
2012)
Glial DmManf
knockdown in 
D. melanogaster
- Appearance of new DmMANF+ 
microglia-like cell type
(Stratoulias & 
Heino, 2015)
Manf-1 knockdown in 
C. elegans
- Changes in innate immunity-
related gene expression
Reduced growth in the presence 
of E. coli
(Hartman et
al., 2019)
Monocyte-
macrophage-specific 
MANF ko
- Healthy: Number of M1 
macrophages in the spleen ↑
Hepatic fibrosis: Number of M2 
macrophages in the spleen ↑
(Hou et al.,
2019)
Manf+/- mouse - Liver inflammation and damage ↑ (Sousa-Victor
et al., 2019)
Hepatocyte-specific
Manf ko mouse
- Liver IL-1α, TNF-α ↑ (Liu et al.,
2019)
Other
S. domuncula SDMANF colocalization with Toll-
like receptor
(Sereno et al.,
2017)
AAV, adeno-associated virus; C3, complement component 3; dMCAo, distal middle cerebral 
artery occlusion; Emr1, EGF module-containing mucin-like receptor; FLS, fibroblast-like
synoviocytes; GRP78, 78 kDa glucose-regulated protein; IL, interleukin; ko, knockout; LPS, 
lipopolysaccharide; M1, classically activated; M2, alternatively activated; MAPK, mitogen-
activated protein kinase; MCAo, middle cerebral artery occlusion; NF-κB, nuclear factor 
kappa-light-chain-enhancer of activated B cells; NSC, neural stem cell; OGD, oxygen-glucose 
deprivation; S100A8, calgranulin A; S100A9, calgranulin B; TBI, traumatic brain injury; TNF-
α, tumor necrosis factor α; UPR, unfolded protein response; wt, wild type 
2.5 CLINICAL TRIALS IN ISCHEMIC STROKE
As in many neurodegenerative diseases, clinical development of novel 
therapies for ischemic stroke has been extremely challenging and the stroke 
research field is infamous for failures in clinical trials. Despite vast efforts, only 
the thrombolytic agent alteplase has reached clinical use globally. Although 
not a pharmacological approach, mechanical thrombectomy is also widely 
used in the hyperacute phase of ischemic stroke in addition to thrombolysis. 
Additionally, the free-radical scavenger edaravone has been approved for 
clinical use in the treatment of hyperacute ischemic stroke in Japan in 2001 
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(Edaravone Acute Infarction Study, 2003; Aoki et al., 2017). Most of the 
experimental therapies have been focused on neuroprotective strategies and 
targeting the hyperacute mechanisms of ischemic stroke, such as 
excitotoxicity, oxidative stress, calcium overload, and apoptosis, aiming to 
salvage the penumbra tissue and prevent the expansion of the infarct core. 
However, the therapeutic time window is narrow, a few hours at most, and 
often not achievable in patients. The preclinical evidence is typically from a 
very acute time point and some of the clinical trials may have failed because of 
too delayed treatment (Chamorro et al., 2016).   
Experimental models of ischemic stroke are able to depict the major 
pathophysiological hallmarks of human stroke but these models have many 
shortcomings as well. Most of the preclinical studies are performed in healthy, 
young, male animals and do not reflect the heterogenous patient population 
with comorbidities, such as hypertension and diabetes, and comedication. 
Usually, the ischemic lesion is standardized as in the MCAo model, unlike in 
patients with large variability in the lesion size and location. There are also 
differences in the immune system between rodents and humans, and a 
surgically induced infarct may further trigger immune responses that 
confound stroke pathophysiology. Brain and vascular anatomy, as well as 
functional organization of the brain, differ between species. Therefore, it is 
important to take these differences into account when translating from bench 
to bedside. 
2.5.1 IMMUNOMODULATORY THERAPIES
The therapeutic molecules investigated in this thesis, MANF and (+)-
naloxone, have shown immunomodulatory effects and inflammation is indeed 
one of the major therapeutic targets in ischemic stroke. To evaluate the 
potential of these interventions, the main clinical studies focused on anti-
inflammation are reviewed (Table 6).  
The most positive clinical outcomes have been accomplished with the 
antibiotic minocycline, the IL-1 receptor antagonist (IL-1ra) anakinra, and the 
leukocyte inhibitors fingolimod and natalizumab. Several open-label studies 
have been conducted with minocycline showing beneficial effects on 
neurological functions (Lampl et al., 2007; Padma Srivastava et al., 2012; 
Amiri-Nikpour et al., 2015) and meta-analyses support the efficacy of 
minocycline in the treatment of hyperacute ischemic stroke (Malhotra et al., 
2018; Sheng et al., 2018). Anakinra was found to decrease neutrophil, total 
leukocyte, CRP, and IL-6 levels in the blood, and to improve clinical outcomes 
in patients with cortical infarcts in the first randomized phase II study (Emsley 
et al., 2005). Unfortunately, a more recent phase II study suggested a possible 
interaction between anakinra and rtPA leading to a worse outcome (Smith et 
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al., 2018). A phase II trial on natalizumab, an antibody against the adhesion 
molecule very late antigen-4 (VLA-4) expressed in T cells and monocytes, did 
not find an effect on the infarct volume, but patients treated with natalizumab 
had better functional recovery at one and three months post-stroke compared 
to placebo (Elkins et al., 2017). Several pilot studies on fingolimod, a 
lymphocyte inhibitor, have found it to decrease infarct growth and to improve 
functional recovery either with or without alteplase treatment (Fu et al., 2014; 
Zhu et al., 2015; Tian et al., 2018). 
Despite some positive outcomes in the stroke clinical trials with 
immunomodulatory drugs, none of the treatments have yet reached the 
market. However, the confirmed safety and potential efficacy of 
immunomodulation in stroke patients builds hope that it is a feasible 
treatment strategy also in the clinics. Additionally, cell-based therapies, such 
as transplantation of mesenchymal or neural stem cells, are increasingly 
investigated in the treatment of stroke and immunomodulation has been 
proposed as one of the mechanisms behind their potential recovery-promoting 
actions (Trounson & McDonald, 2015; Satani & Savitz, 2016; Liska et al., 
2017).
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Table 6. The outcome of clinical studies using immunomodulatory therapies in 
ischemic stroke patients. Time indicates hours from symptom onset until initiation of 
therapy.
Therapy Time Outcome Reference
Immunosuppressant
Cyclosporine ≤5h No effect (Nighoghossian et 
al., 2015)
Dexamethasone <24h No effect (Ogun & Odusote, 
2001)
Dexamethasone + dextran 24-48h No effect (Kaste et al., 1976)
Antibiotic
Minocycline ≤6-24h Improved 
neurological function 
(Lampl et al., 2007; 
Padma Srivastava
et al., 2012; Amiri-
Nikpour et al., 2015)
Dapsone ≤12h Improved 
neurological function
(Nader-Kawachi et 
al., 2007)
Neutrophil adhesion inhibitor
CD11b/CD18 antagonist 
(UK-279,276)
≤6h No effect (Krams et al., 2003)
Anti-ICAM-1 antibody 
(enlimomab)
≤6h Worse outcome (Enlimomab Acute 
Stroke Trial, 2001)
IL-1 receptor antagonist 
(anakinra) 
≤6h Improved 
neurological function
(Emsley et al.,
2005)
Anti-CD18 antibody
(Hu23F2G)
≤12h No effect (del Zoppo, 2010)
Leukocyte inhibitor
Anti-VLA-4 antibody 
(natalizumab)
≤9h Improved 
neurological function
(Elkins et al., 2017)
Sphinogosine-1-phosphate 
receptor modulator
(fingolimod)
7-62h;
≤4.5h; 
≤6h
Improved 
neurological function
(Fu et al., 2014; Zhu
et al., 2015; Tian et 
al., 2018)
Other
Naloxone see chapter 2.3
Paracetamol <12h No effect (den Hertog et al.,
2009; de Ridder et 
al., 2017)
CD, cluster of differentiation; ICAM-1, intercellular adhesion molecule 1; IL, interleukin; VLA-
4, very late antigen-4
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3 AIMS OF THE STUDY
There is a great need for novel therapies for ischemic stroke since despite 
decades of research there is still no drug that could promote the functional 
recovery of patients. The aim of this thesis was to study whether post-stroke 
treatment with MANF or (+)-naloxone, both associated with 
immunomodulatory effects, could promote recovery. In the clinics, the 
therapy can rarely be given preventively and it is, therefore, vital to study drug 
candidates in the context of post-stroke treatment. 
 
The specific aims of the study were: 
 
1) To characterize the time course of neuroinflammation in the rat dMCAo 
model and MANF protein expression in the dMCAo model and in the 
infarcted human brain.   
 
2) To determine whether the secondary pathology of the thalamus in the rat 
dMCAo model is associated with hyperalgesia and can be rescued with 
MANF or its homolog CDNF. 
 
3) To investigate whether post-stroke intranasal (+)-naloxone delivery 
promotes recovery in the rat dMCAo model.  
 
4) To study whether intracranial post-stroke delivery of MANF promotes 
recovery in the dMCAo model and what is the molecular mechanism 
behind its action.  
 
5) To examine whether the intranasal delivery of MANF is neuroprotective in 
the rat dMCAo model.
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4 MATERIALS AND METHODS
The methods that were used in the studies are listed in Table 7. A detailed 
description of the methods can be found in the original publications and their 
supplementary materials. The methods in which the author was involved in 
are marked with an asterisk. 
 
Table 7. Methods used in the studies.
Method Original study
Animal experiments
distal middle cerebral artery occlusion (dMCAo) model in rat* I, II, III, IV
dMCAo model in mouse II, III
Stereotaxic injections* II, IV
Laser Doppler flowmetry* III
Intranasal administration of drugs* I, III
Behavioral assays*
- Neurological tests I, II, III, IV
- Cylinder test II
- Open field test I, II, III
- Hyperalgesia tests IV
Evans blue albumin extravasation* III
Mini-osmotic pump implantation I, II
Immunological detection
Immunohistochemistry/Immunofluorescence* I, II, III, IV
Enzyme-linked immunosorbent assay (ELISA)* I, III
Imaging and morphometric analyses
Confocal microscopy* II, III
Magnetic resonance imaging (MRI) II
Infarct volume/area analysis* I, II, III, IV
Cell counting* I, II, IV
Stereology I
Cell culture experiments
Magnetic activated cell sorting (MACS)* I
Production of viral vectors II
Others
Real-time quantitative polymerase chain reaction (qPCR) II
RNA sequencing and transcriptome analysis II
125I-labeling of MANF III
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4.1 ANIMALS 
Male Sprague Dawley rats and male C57BL/6NHsd mice (Harlan/Envigo, 
Netherlands) were used for the experiments. In addition, gene-modified 
NestinCre/+::Manffl/fl male mice with Manf lacking from neural lineage cells 
and control Manffl/fl male mice were used. 
The animals were housed in groups of 2-5 under a 12h/12h dark-light cycle 
with ad libitum access to food and water. All the animal experiments were 
approved by the national Animal Experimental Board (protocol approval 
numbers ESAVI/5459/04.10.03/2011, ESAVI/7812/04.10.07/2015, and 
ESAVI/13959/2019) and conducted according to the 3R principles of EU 
directive 2010/63/EU, and Finnish legislation. 
4.2 METHODOLOGICAL CONSIDERATIONS
4.2.1 EXPERIMENTAL FOCAL MODELS OF ISCHEMIC STROKE
 
Experimental focal ischemic stroke is most typically induced in mouse or rat 
by MCAo [see in (Carmichael, 2005)]. In the most used model, a coated 
filament suture is inserted into the carotid artery to block the origin of the 
middle cerebral artery (Belayev et al., 1996) and can be left in place to induce 
permanent ischemia, or withdrawn usually after 30-120 min to induce 
ischemia-reperfusion injury. Depending on the duration of the occlusion, the 
filament MCAo causes a large lesion between 21-45% of the ipsilateral 
hemisphere that includes regions of the striatum and cortex, and after 60 min 
also hypothalamus, thalamus, hippocampus, and midbrain. In humans, a 
similar sized lesion would be fatal in most cases, and moreover, striatal strokes 
are rare in patients (Delavaran et al., 2013). A variation of the model was 
developed by Tamura et al. where the occlusion is done by directly ligating a 
proximal stem of the middle cerebral artery through a craniotomy, leading to 
more restricted ischemic damage to the cortex and also striatum (Tamura et 
al., 1981). In the dMCAo model, the distal branch of the middle cerebral artery, 
responsible for the blood flow to the cortex, is ligated directly through a 
craniotomy (Chen et al., 1986). To increase the consistency of the lesion, either 
one or both common carotid arteries can be occluded. The dMCAo model 
produces a smaller lesion than the filament MCAo since blood flow to the 
striatum is not blocked and the infarction is restricted to the cortex. In all of 
these models, ischemia can be either permanent or transient with varying 
occlusion durations. Mimicking more the human pathophysiology, the 
embolic MCAo can be caused by either injection of microspheres or 
macrospheres into the blood circulation (Miyake et al., 1993; Gerriets et al., 
2003), or by induction of thromboembolic clots, to block blood flow to the 
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middle cerebral artery (Zhang et al., 1997). The thromboembolic clot model 
can be used especially to test new thrombolytic treatments. The downside of 
thromboembolic models is larger variability and the need to use more animals 
than in the mechanical occlusion models (Ansar et al., 2014). 
In addition to models involving the occlusion of the middle cerebral artery, 
models with high specificity in size and location of the ischemic lesion have 
been developed. In the photothrombotic model, a photosensitive dye (Rose 
Bengal) is injected intravenously or intraperitoneally and irradiated through 
the skull to induce a small cortical lesion (Watson et al., 1985). The photo-
activated dye causes damage to endothelial cells that leads to platelet 
aggregation and thrombi formation causing interruption of local blood flow. 
Endothelin-1 is a vasoconstrictor peptide that can be injected stereotaxically 
into the brain parenchyma to create an ischemic lesion in the area of interest 
(Sharkey et al., 1993).  
4.2.2 DISTAL MIDDLE CEREBRAL ARTERY OCCLUSION (dMCAo)
MODEL
 
We chose to use a focal cortical stroke model by occluding the distal middle 
cerebral artery as the model produces cortical infarcts of clinically relevant 
size, has low mortality, and the possibility for long-term follow-up. The more 
frequently used intraluminal MCAo model produces large striatal infarcts and 
is associated with high mortality and hyperthermia caused by hypothalamic 
damage, which may confound results and does not depict common features of 
human infarcts (Carmichael, 2005). As a limitation, the dMCAo model 
requires craniotomy which may damage the BBB and influence edema-
induced pathophysiology that would occur within the closed skull. Surgical 
procedures and anesthesia may induce e.g. inflammation and peripheral 
effects, and sham-operated animals are a valuable control group to recognize 
confounding factors. Anesthesia can generally be criticized as human strokes 
rarely occur under anesthesia.  
We did not routinely monitor cerebral blood flow (CBF) to confirm 
successful ligation. CBF monitoring is important, especially when studying 
neuroprotective treatments that are given before the induction of ischemia and 
could, therefore, influence the CBF giving a false-positive result. CBF was 
measured with Laser Doppler Flowmetry in study III where only 1/20 animals 
did not have significant (<65%) reduction in CBF, indicating that unsuccessful 
ligation is relatively rare. However, the methods used for CBF monitoring give 
only an arbitrary estimation of the blood flow and not a true measure. 
Overall, ischemic stroke models using mechanical occlusion have been 
criticized for not reproducing the natural cause of infarct (Hossmann, 2012). 
Also, reperfusion by occlusion removal is immediate and does not depict the 
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slow spontaneous or thrombolytics-induced reperfusion in humans, although 
the mechanical occlusion models could be used to mimic mechanical 
thrombectomy. Ideally, preclinical testing should be done in models 
representing the clinical situation, e.g. in thromboembolic models or 
spontaneous hypertension-induced stroke models, but due to high variability, 
the use of these models would require high animal numbers and could still 
produce false-negative results. Also, we have used young healthy animals 
whereas stroke patients are usually elderly and suffer from comorbidity. 
However, the dMCAo model is technically challenging to perform in aged 
animals and the mortality is high. Therefore, it can be considered justified to 
use the highly reproducible mechanical occlusion models and young animals 
for initial testing of new therapeutics but the efficacy should be verified in 
other models and in aged animals later on before proceeding to clinical 
studies.  
4.2.3 DRUG DELIVERY
 
The drugs were administered either intracranially in a stereotaxic surgery or 
intranasally (Table 8). Both of these methods require anesthesia for which 
isoflurane was used. Isoflurane has neuroprotective properties (Sakai et al., 
2007), opens the BBB (Tetrault et al., 2008), and activates tropomyosin 
receptor kinase B (TrkB), the receptor for BDNF, and other intracellular 
signaling routes (Antila et al., 2017). Therefore, it is vital to include a control 
group receiving the same amount of isoflurane as the therapeutic group. In 
study I, an additional no treatment group was included to control for the effect 
of repeated isoflurane administration during chronic intranasal 
administration. 
When performing stereotaxic injections, it is important to consider the 
mechanical damage the needle may cause in the brain. The damage may be 
substantial (Penttinen et al., 2016) and we started to use a thin 33G needle to 
minimize the mechanical injury. Thin glass capillaries could be another option 
with less mechanical damage. Intracranial delivery is not optimal for clinical 
use but in initial preclinical studies, it can be considered reasonable in terms 
of confirming the access of the investigated drug into the therapeutic target 
area in the brain. 
Besides absorbing systemically from the nasal cavity, intranasally delivered 
molecules can bypass the BBB and access the central nervous system via 
several pathways, including the olfactory and trigeminal nerves, vascular and 
cerebrospinal fluid pathways, and lymphatic system (Thorne et al., 2004; 
Hanson & Frey, 2008; Lochhead & Thorne, 2012). There is evidence that 
intranasally delivered peptides reach the CNS in humans (Reger et al., 2008) 
even though the greater distances and different anatomy of nasal pathways 
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pose problems for bioavailability of intranasal drugs when comparing to 
rodents. Also, variability in the absorption efficacy between individual subjects 
is greater after intranasal delivery than with other delivery methods. 
Intranasal delivery of naloxone was used as an intranasal formulation 
(Narcan®) is already on the market in the US. Intranasal delivery of rhMANF 
was used as an alternative non-invasive administration technique. 
 
Table 8. Study design for therapeutic drug delivery.
Study Design Dose Coordinates
A/P; L/M; D/V
Treatment 
groups
I Intranasal naloxone 
delivery twice daily for 
one week starting on 
post-stroke day 1
14 x 
0.0008 -
0.8 mg/kg
- No treatment
Vehicle (H20)
(+)-naloxone: 
0.0008 mg/kg
0.008 mg/kg
0.08 mg/kg
0.32 mg/kg
0.8 mg/kg
(-)-naloxone: 
0.32 mg/kg
II Intracranial AAV-MANF
injection into the peri-
infarct region on post-
stroke day 2
2 x 2.5 μl 1.6; 2.2; -5.0
and
-0.4; 4.0; -5.0
Vehicle (PBS)
AAV7-GFP (1.1 x 
1013 vg/ml)
AAV7-MANF (8.1 
x 1012 vg/ml)
II Intracranial infusion of 
rhMANF into the peri-
infarct region starting on
post-stroke day 3
3 μg/day 
for 14 
days
−0.5; +1.9; −2.5 Vehicle (PBS)
rhMANF
III Intranasal rhMANF 
delivery 12h before 
dMCAo, 15 min before 
dMCAo and immediately 
after reperfusion 
3 x 7 μg or
3 x 20 μg
- Vehicle (PBS)
rhMANF
IV Intracranial rhCDNF or 
rhMANF injection into the 
thalamus on post-stroke 
day 7
1 x 10 μg 
in 4 μl
-3.0; -3.0; -6.0 Vehicle (PBS)
rhCDNF
rhMANF
A/P, anteroposterior; AAV, adeno-associated virus; dMCAo, distal middle cerebral artery 
occlusion, D/V, dorsoventral; GFP, green fluorescent protein; L/M, lateromedial; PBS, 
phosphate-buffered saline; rh, recombinant human
4.2.4 BEHAVIORAL ASSAYS
 
The behavioral tests assessing functional impairment after ischemic stroke 
should be chosen based on the location of the ischemic lesion. Since the 
dMCAo model produces an infarct located on the cortex responsible mainly 
for sensory and motor functions, we focused on sensorimotor tests. Typically, 
the tests are based on the asymmetry in sensorimotor functions after a 
unilateral lesion.  
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An important issue in rodent models is the rapid recovery of the animals, 
and behavioral deficits usually resolve within 3-4 weeks in rats (Balkaya et al., 
2018). Additionally, compensation may be a problem in long-term behavioral 
testing and can be erroneously considered as behavioral recovery. For long-
term behavioral monitoring of stroke recovery, skilled forelimb reaching tasks, 
e.g. Monotya’s staircase test, are considered the most appropriate for detecting 
chronic sensorimotor impairments but are time-consuming and require 
training of the animals (Corbett et al., 2017; Balkaya et al., 2018). In this 
thesis, only relatively short-term behavioral testing was performed for up to 2-
3 weeks post-stroke when the deficits are still clearly present.    
Body asymmetry test (Borlongan et al., 1995a) and modified Bederson’s 
score (Bederson et al., 1986b) were used to evaluate neurological deficits as 
these tests are fast to perform and have been shown to reflect the infarct size 
(Bederson et al., 1986b; Persson et al., 1989; Shen & Wang, 2010). Other tests 
used were the cylinder test, which measures the deficits in contralateral paw 
use, and spontaneous locomotor activity. Spontaneous locomotor activity is 
more a measure of general animal well-being, and only vertical activity has 
been shown to correlate with the infarct size (Shen & Wang, 2010).  
The body asymmetry test was originally developed by Borlongan and 
Sandberg for a drug-free evaluation of rotational behavior in the unilateral 6-
OHDA lesion model of Parkinson’s disease (Borlongan & Sanberg, 1995). The 
use of the test was soon extended to other toxin models and ischemic stroke 
(Borlongan et al., 1995a; Borlongan et al., 1995b). In the body asymmetry test, 
the rat is lifted above the testing table by the tail and the number of 
contralateral turnings of the head and upper body are counted from 20 trials. 
The maximum impairment is 20 contralateral turns whereas unlesioned 
animals typically score 10 contralateral turns by turning in each direction with 
equal frequency. The body asymmetry has been shown to positively correlate 
with the infarct volume (Shen & Wang, 2010). The test has been criticized for 
unpredictable changes in the preferred turning direction (Ingberg et al., 2015), 
but we have never encountered problems when using the dMCAo model. 
The modified Bederson’s score is based on scoring neurological deficits 
according to the 3-point scale: 0 = no observable deficit; 1 = rats show 
decreased resistance to lateral push; 2 = rats keep the contralateral forelimb 
to the breast and extend the other forelimb straight when lifted by the tail in 
addition to behavior in score 1; 3 = rats twist the upper half of their body 
towards the contralateral side when lifted by the tail in addition to behavior in 
other scores. The neurological score has been shown to positively correlate 
with the infarct size (Bederson et al., 1986b; Persson et al., 1989; Rogers et al., 
1997).  
As a limitation, the neurological tests based on scoring are subjective and 
should therefore always be performed by the same blinded evaluator. The body 
asymmetry test or Bederson’s score does not measure fine motor skills and the 
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deficits resolve spontaneously over time, making the tests unsuitable for long-
term behavioral monitoring (Balkaya et al., 2018).  
The cylinder test is based on spontaneous exploratory behavior in a 
Plexiglas cylinder, where the number of ipsilateral and contralateral forepaw 
touches to the cylinder walls are counted during the 5-10 minutes observation 
period. The test is objective, easy, and relatively fast to perform. The cylinder 
test is also considered to be suited for long-term assessment of motor function 
(Schallert et al., 2000) and is not influenced by behavioral compensation 
(Corbett et al., 2017), however, repeated use of the test can cause habituation 
and a decrease in exploratory behavior (Balkaya et al., 2018).  
4.2.5 IMMUNOHISTOCHEMISTRY AND QUANTITATIVE ANALYSES
 
For the studies, both paraffin and free-floating sections were used. Embedding 
in paraffin allows the use of thin 5 μm sections with only one cell layer which 
enables easy acquirement of high-quality images and clear-cut image analysis, 
but the technique is laborious. Free-floating cryosections are cut in 40 μm 
thickness with multiple cell layers which makes one-dimensional image 
analysis challenging, but the technique is fast and allows efficient processing 
of large sample numbers. 
While using methods based on immunological detection, it is of utmost 
importance to verify that the antibodies used are specific. This can be done by 
using proper controls, for example, tissue from ko animals that do not express 
the antigen of interest, or using preadsorption with the antigen before 
applying the antibody on the tissue analyzed. Also, a control for unspecific 
binding of immunoglobulins should be included.  
Immunostaining offers some advantage over methods such as flow 
cytometry and western blot by allowing the analysis of the precise location of 
the antigen of interest within the tissue and within a cell type. However, 
quantitative analysis from immunostained tissue is always a mere estimation 
which is strongly influenced by the number of sections quantified and the 
method of counting. Moreover, immunohistochemical reaction is not a linear 
process due to saturation and hence, the intensity of the staining does not 
necessarily correlate with the amount of the antigen (Corbett et al., 2017). 
Therefore, immunohistochemical methods can be used for counting the 
number of immunopositive objects but are not recommended for quantifying 
the intensity of the staining. Stereology, which allows quantification of 3D 
material from 2D images, is considered an accurate method for cell counting 
but is very time consuming and subjective. The method involves random 
sampling of sites from the tissue of interest, followed by manual recognition 
and counting of cells in these sites, and finally, the cell numbers per volume 
are obtained based on the thickness, area, and the number of sections 
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sampled. Recently, several algorithms for automated analysis of digital images 
have been developed and shown to highly correlate with the cell numbers 
counted manually using stereology and offer a high-throughput option for 
stereology (Penttinen et al., 2016; Penttinen et al., 2018). Without developing 
an algorithm, digital images of stained sections can be analyzed with different 
image analysis software (e.g. open-source program ImageJ) that automatically 
count the number of objects that exceed a certain intensity threshold. The 
advantage of using these software is that it offers a relatively fast analysis of a 
high number of samples but requires the careful setting of the intensity 
threshold versus background staining for obtaining reliable object counts and 
does not take into consideration the 3D structure of the sample. 
4.2.6 INFARCT VOLUME/AREA ANALYSIS 
 
2,3,5-triphenyl-2H-tetrazolium chloride (TTC) staining has been shown to 
measure infarct size as accurately as histological methods 24h after stroke 
(Bederson et al., 1986a). The TTC staining method is based on a color reaction 
where the white TTC is reduced to a red compound (1,3,5-triphenyl formazan) 
by mitochondrial dehydrogenases. After ischemia-induced mitochondrial 
damage, the infarct area will remain white. At time points earlier than 24h TTC 
staining is not reliable as permanent mitochondrial damage has not yet 
occurred (Bederson et al., 1986a). Also, TTC staining is not suitable for infarct 
volume analysis at later time points where myeloid cells have invaded the 
infarct area as it is not a specific marker for neuronal cell death but measures 
only mitochondrial function. 
In the neuroprotection studies, the rats were sacrificed at day (d)2 post-
stroke, the brains were sliced into seven 2 mm sections, incubated with 2% 
TTC for 15 min, and the total infarct volume was counted by multiplying infarct 
area with the thickness of the section. At later time points, the infarct area was 
quantified using either paraffin or free-floating coronal sections stained with 
anti-neuronal nuclei (NeuN) antibody or cresyl violet. The infarct area was 
recognized as being absent from NeuN- or Nissl-positive neurons and 
expressed as a percentage of the total area of the section to reduce variance 
caused by tissue processing. When quantifying infarct volumes, it is important 
to take into consideration whether edema is present at the time of analysis. 
Brain edema is most pronounced during the first days after ischemic stroke 
which is why edema correction should be used when quantifying d2 infarct 
volumes (Lin et al., 1993). The edema correction was done by measuring the 
area of healthy tissue on the ipsilateral hemisphere and subtracting it from the 
contralateral hemisphere. 
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5 RESULTS
5.1 CHARACTERIZATION OF NEUROINFLAMMATION 
AND SECONDARY PATHOLOGY OF THE THALAMUS 
IN THE dMCAo MODEL (I, IV)
To study the effects of immunomodulation, it is vital to know the temporal and 
spatial characteristics of neuroinflammation in the model used. Therefore, we 
first characterized the dMCAo model we use to induce a focal cortical stroke. 
The neurological deficits could be observed up to d28 post-stroke, but at that 
time point there was already spontaneous recovery in Bederson’s score test 
(IV: Fig. 3B). Histological characterization was performed at d2, d7, d14, d28, 
d56 and d112 post-stroke. 
Morphological activation of Iba1+ (ionized calcium-binding adapter 
molecule 1; a general marker for microglia/macrophages) cells was observed 
at d2 post-stroke mainly in the peri-infarct region with few cells expressing the 
phagocytic marker CD68 (Figure 7A; I: Fig. 2C, D). However, at d7 post-stroke, 
the ischemic cortex was highly covered by activated CD68+ cells (Figure 7A; I: 
Fig. 2F). At the same time point, morphological activation of Iba1+ cells was 
also detected in the ipsilateral striatum and thalamus but few cells were 
CD68+ (Figure 7A; I: Fig. 2E, F). At d14 and d28 post-stroke the number of 
CD68+ cells was significantly elevated in the ipsilateral thalamus (Figure 7A-
B; I: Fig. 2H, J), and phagocytic cells were observed in the thalamus until post-
stroke d112 (Figure 7A-B; I: Fig. 2N).  
Astrocytes, identified as expressing glial fibrillary acidic protein (GFAP), 
were activated in the peri-infarct region starting from d2 post-stroke (Figure 
7A; I: Fig. 4B), and in the ipsilateral striatum and thalamus starting from d7 
post-stroke (Figure 7A; I: Fig. 4C). Intense thalamic astrogliosis was observed 
for up to d112 post-stroke (Figure 7A; I: Fig. 4G).  
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Figure 7. Immunohistochemical characterization of neuroinflammation and 
secondary neuronal loss in the dMCAo rat model. A: Representative images of rat 
brain sagittal sections at different post-stroke time points immunostained with anti-
Iba1, anti-CD68, and anti-GFAP. B: Quantitation of CD68+ cells in the thalamus at 
different time points (n=4). */# p<0.05; * vs. ipsilateral; # vs. contralateral; Kruskal-
Wallis test and Mann-Whitney U test. C: Quantitation of CD68+ cells and D: NeuN+ 
cells in the ipsilateral thalamus in naïve rats and in rats 28 days after sham or stroke 
operation; naïve (n=6), sham (n=9), stroke (n=9). ****/#### p<0.0001; **** vs. sham; 
#### vs. naïve; one-way ANOVA, Bonferroni’s post hoc test. E: Representative 
images of anti-NeuN immunostained sections used for NeuN+ cell counting. The data 
represents the mean ± SEM. Scale bar is 500 μm (E upper row) and 100 μm (E lower 
row). Figure modified from publications I and IV. 
 
We observed a neuronal loss in the ipsilateral thalamus at d14 (24%; I: Fig. 
6B; Figure 13B) and d28 (38%; Figure 7D) post-stroke, simultaneously with 
the peak in the number of CD68+ cells (Figure 7B-C). However, direct 
conclusions on the progression of damage cannot be made as the duration of 
ischemia was different in these d14 and d28 studies, 60 min and 90 min, 
respectively. We confirmed that sham surgery does not cause any detectable 
damage in the thalamus (Figure 7C-D). In the striatum, the CD68+ cells were 
aligned along with axonal bundles and colocalized with myelin basic protein 
(MBP) (I: Fig. 3), implying phagocytosis of myelin in the degenerating axons 
connecting the cortex and thalamus. 
Results 
53 
 
As the thalamus is an important relay station for pain signals, we also 
investigated if the secondary thalamic degeneration would induce 
hyperalgesia. Hyperalgesia has been found after endothelin-1-induced 
primary ischemic damage to the thalamus (Blasi et al., 2015). However, we 
found no hypersensitivity toward mechanical or thermal stimuli compared to 
sham-operated animals at d3, d14 or d28 post-stroke (IV: Fig. 3D-H). 
5.2 CHARACTERIZATION OF ENDOGENOUS MANF 
PROTEIN EXPRESSION AFTER ISCHEMIC STROKE
To study the effects of MANF, it is important to know the temporal and spatial 
characteristics of endogenous MANF expression in the model used, and in 
patients for translational relevance. The post-stroke expression of endogenous 
MANF protein was characterized using immunohistochemistry on tissue 
samples from the infarcted rat, mouse, and human brains.   
5.2.1 ISCHEMIC STROKE INDUCES DELAYED MANF EXPRESSION IN 
MYELOID CELLS (III)
 
Similarly to neuroinflammation, we characterized the MANF protein 
expression pattern in the rat model of dMCAo using immunohistochemistry at 
d2, d7, d14, d28, d56, and d112 post-stroke. MANF immunoreactivity was 
increased in the peri-infarct area at all time points (III: Fig. 1b-g). In 
comparison to the contralateral hemisphere, MANF immunoreactivity was 
markedly decreased in the infarct core at d2 in rats (Figure 8A, C) but 
increased in the corpus callosum (III: Fig. 2). However, MANF was strongly 
upregulated in the infarct core at d7 (Figure 8A) and in the ipsilateral thalamus 
at d14 (Figure 8A; III: Fig. 1d), coinciding with the peak expression of 
phagocytic marker CD68 (Figure 7A). The colocalization of MANF and CD68 
was verified with double immunofluorescence and confocal microscopy. In the 
contralateral cortex, MANF colocalized with NeuN (Figure 8B) but at d2 in the 
ischemic cortex, the NeuN+ cells had lost MANF expression (Figure 8C). 
However, at d2 and d14, MANF colocalized with CD68 in the ischemic cortex 
and in the ipsilateral thalamus (Figure 8D, E). Only a few MANF expressing 
astrocytes (GFAP+ cells) were observed in the ischemic brain. 
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Figure 8. Characterization of endogenous MANF expression pattern in rat brain in 
the dMCAo model. A: Representative images of temporal and spatial MANF 
expression in sagittal rat brain paraffin sections at different time points after ischemic 
stroke. B: Double immunofluorescence staining of the contralateral cortex, C:
ischemic cortex, and D: peri-infarct area at 2 days post-stroke, and E: of ipsilateral 
thalamus at 14 days post-stroke. NeuN and MANF colocalize in the contralateral (B)
but not in the ischemic cortex (C). CD68 and MANF colocalize in the peri-infarct area 
(D) and in the ipsilateral thalamus (E). Scale bar is 10 μm. Unpublished results.
 
We investigated whether circulating MANF could be used as a biomarker 
in ischemic stroke. Endogenous MANF levels were measured from mouse 
serum at 1h, 6h, 24h, and 48h after permanent dMCAo but we found no 
significant differences compared to mice without any ischemic damage (Figure 
9).  
Figure 9. Endogenous MANF serum levels are not altered after permanent cerebral 
ischemia. Endogenous MANF (mMANF) concentrations were measured from mouse 
serum at different time points after permanent dMCAo with mouse MANF ELISA (n=3-
6). The data represents the mean ± SEM. Unpublished result.   
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5.2.2 MANF EXPRESSION IS INDUCED IN NestinCre/+::Manffl/fl
KNOCKOUT MICE AFTER ISCHEMIC STROKE (III)
 
Gene-modified NestinCre/+::Manffl/fl mice were used to analyze post-stroke 
MANF expression in the absence of Manf from neural lineage cells. MANF 
immunoreactivity was lacking in the contralateral cortex of 
NestinCre/+::Manffl/fl mice (Figure 10B, E) whereas in the Manffl/fl control mice 
MANF was widely expressed in cortical neurons (Figure 10A). Also, the mRNA 
levels of Manf were very low in the contralateral hemisphere of 
NestinCre/+::Manffl/fl mice (II: Fig. 4J). NestinCre/+::Manffl/fl mice had larger 
infarcts on d2 post-stroke compared to control Manffl/fl mice (II: Fig. 4K), 
indicating a protective role for endogenous neuronal MANF in ischemia.
However, MANF expression was induced in the infarct core, peri-infarct 
region, and the ipsilateral thalamus of NestinCre/+::Manffl/fl mice at d14 post-
stroke (Figure 10B) similarly to control mice (Figure 10A). Double 
immunofluorescence staining of MANF and Iba1 confirmed the post-ischemic 
MANF upregulation occurs in microglia/macrophages of the ischemic cortex 
in the NestinCre/+::Manffl/fl mouse (Figure 10F).  
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Figure 10. MANF protein expression is induced in microglia/macrophages of the
NestinCre/+::Manffl/fl knockout mouse brain after ischemic stroke. Anti-MANF 
immunostaining of Manffl/fl control (A) and NestinCre/+::Manffl/fl knockout (B), and anti-
MANF and anti-Iba1 double immunofluorescence staining of the contralateral cortex 
and peri-infarct cortex of Manffl/fl control (C, D) and NestinCre/+::Manffl/fl knockout (E, F)
mouse brain at d14 after permanent dMCAo. A-B: scale bar is 100 μm. C-F: Scale 
bar is 10 μm. Unpublished results.
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5.2.3 ISCHEMIC STROKE INDUCES DELAYED MANF PROTEIN 
EXPRESSION IN BRAIN IMMUNE CELLS IN HUMANS (III)
 
We characterized MANF and CD68 expression from consecutive post mortem 
tissue sections of patients deceased approximately 3 days, 1 week, and 2 weeks 
after ischemic stroke (III: Table 1). In the contralateral side of the infarcted 
brains, MANF expression was mainly neuronal (Figure 11A, C, E). However, 
neuronal MANF expression was lost in the infarct core at d3 (Figure 11G), as 
we also found to occur in the rat dMCAo model. MANF expression remained 
very low in the ischemic area at 1 week post-stroke (Figure 11I). However, at 2 
weeks post-stroke there were high numbers of MANF+ and CD68+ round cells 
in the infarct region (Figure 11K, L).  
Overall, the number and location of MANF+ and CD68+ cells correlated in 
the infarcted hemisphere. However, we also found CD68+ cells in the 
contralateral side, especially in the white matter, but the morphology of the 
cells was more ramified than in the infarcted hemisphere. Some of these white 
matter cells were also MANF+ but less than in the infarcted hemisphere. 
Elevated cyclo-oxygenase 2 and TNF-α immunoreactivity, and increased 
density of intercellular adhesion molecule 1-expressing microvessels have 
been previously described in these same contralateral hemisphere samples 
when comparing to non-infarcted control brains (Lindsberg et al., 1996; 
Sairanen et al., 1998; Sairanen et al., 2001). These data suggest that 
inflammatory changes also occur in the contralesional human brain after 
ischemic stroke, and stroke-induced brain herniation and neuroplastic events 
may influence the contralateral hemisphere. However, CD68+ cells have also 
been found in the healthy brain, particularly in the white matter, and shown 
to increase with age (Hendrickx et al., 2017; Hopperton et al., 2018), and the 
contralateral CD68 expression in the infarcted brains may represent basal 
levels in the human brain as well. 
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Figure 11. MANF protein expression correlates with CD68 expression at 2 weeks 
post-stroke in the infarcted human brain. Anti-MANF and anti-CD68 immunostaining 
of human cerebral tissue from ischemic stroke patients around 3 days, 1 week and 2
weeks post-stroke. A-F: Contralateral hemisphere of the ischemic brain. G-L: The 
ischemic region. Scale bar is 1000 μm and 50 μm. Unpublished results.
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5.3 EFFECTS OF POST-STROKE INTRANASAL (+)-
NALOXONE DELIVERY IN THE dMCAo MODEL
The opioid antagonist naloxone has shown non-stereoselective 
immunomodulatory effects potentially beneficial in ischemic stroke. Before 
these effects were known, acute naloxone therapy was in clinical trials and 
found safe but ineffective. However, naloxone should be further investigated 
in the context of long-term post-stroke treatment. Furthermore, we 
concentrated on the (+) enantiomer that has a very low affinity for opioid 
receptors in order to avoid any potential side effects from opioid receptor 
antagonism. 
5.3.1 POST-STROKE INTRANASAL DELIVERY OF (+)-NALOXONE 
REDUCES BEHAVIORAL DEFICITS (I)
 
Intranasal (+)-naloxone was administered twice daily for 7 days starting at d1 
post-stroke (Figure 12B). The (+)-naloxone-treated rats had significantly 
milder neurological deficits at d10 and d14 compared to vehicle and no 
treatment groups (Figure 12C-D). (-)-Naloxone had a similar effect (Figure 
12E-F). The effect of (+)-naloxone was dose-responsive (I: Fig. 5D-E). In 
addition, spontaneous horizontal activity at d14 was significantly increased in 
the (+)-naloxone-treated rats compared to no treatment group (I: Fig. 5G). 
Figure 12. Post-stroke treatment with naloxone reduces behavioral deficits. A: (-) and 
(+) enantiomers of naloxone. B: Intranasal naloxone was started on post-stroke day
(D) 1 and continued for 7 days twice daily. Behavioral recovery was assessed (B)
until day 14. C: Body asymmetry test and D: Bederson’s score after (+)-naloxone 
treatment. Vehicle (n=25), no treatment (n=13), (+)-naloxone 0.32 mg/kg (n=27), 
Kruskal-Wallis test and Mann-Whitney U test. E: Body asymmetry test and F:
Bederson’s score after (-)-naloxone treatment. Vehicle (n=11), (-)-naloxone 0.32 
mg/kg (n=7), Mann-Whitney U test. * vs. vehicle; # vs. no treatment; # (p<0.05), **/## 
(p<0.01); ***/### (p<0.001). The data represents the mean ± SEM. Figure modified 
from publication I.
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Pretreatment with three doses (0.32 mg/kg) of intranasal (+)-naloxone had 
no significant effect on the infarct volume (I: Fig. 8A-B). We also investigated 
if a more delayed intranasal (+)-naloxone therapy, started on d3, would have 
an effect on behavioral recovery (I: Fig. 8C). There was a trend (p=0.066, 
Mann-Whitney U test) for milder deficits in the body asymmetry test on d16, 
but not any statistically significant difference compared to the vehicle group 
(I: Fig. 8D). In addition, chronic intraventricular delivery of (+)-naloxone 
starting on d2 post-stroke and continuing for 12 days was investigated (I: Fig. 
8E) but there were no differences in the neurological deficits between (+)-
naloxone and vehicle groups (I: Fig. 8F). These data imply the therapeutic 
window is around 24h post-stroke when the infarct is still developing (Li et al., 
2000; Liu et al., 2009). 
5.3.2 POST-STROKE INTRANASAL DELIVERY OF (+)-NALOXONE
REDUCES INFARCT VOLUME AND NEUROINFLAMMATION (I)
 
The infarct size, secondary neuronal loss of the thalamus, and the amount of 
Iba1+ cells in the striatum and thalamus were quantified at d14 post-stroke. 
(+)-Naloxone decreased the infarct size and the neuronal loss in the ipsilateral 
thalamus (Figure 13A-D) as well as the number of Iba1+ cells in the ipsilateral 
striatum and thalamus (Figure 13E-G). (+)-Naloxone had no effect on the 
number of Iba1+ cells in the contralateral striatum (I: Fig. 7B). 
Figure 13. Post-stroke treatment with intranasal (+)-naloxone reduces neuronal loss 
and neuroinflammation. A: Average infarct area (Student’s t-test) and B: number of 
NeuN+ cells in the ipsilateral thalamus compared to the contralateral side (Kruskal-
Wallis test and Mann-Whitney U test) at post-stroke day 14. C: Representative 
images showing the infarct area and D: the ipsilateral thalamus in anti-NeuN 
immunostained sections. E: Number of Iba1+ cells in the ipsilateral striatum (one-way 
ANOVA, Bonferroni’s post hoc test) and F: Iba1 immunoreactive area in the ipsilateral
thalamus compared to the contralateral side (Kruskal-Wallis test and Mann-Whitney 
U test). G: Representative images of ipsilateral striatum and thalamus. Naïve (n=6); 
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control (n=18); (+)-naloxone (n=10). * vs. control; # vs. naïve; * (p<0.05); **/## 
(p<0.01); *** (p<0.001). Scale bar is 150 μm (D), 1000 μm (G, upper row) and 50 μm 
(G, lower row). The data represents the mean ± SEM. Figure modified from 
publication I.
We conducted an in vitro experiment on CD11b+ (marker for microglia and 
macrophages) cells isolated from the ischemic cortex on d7 post-stroke. After 
LPS treatment, TNF-α secretion was increased in the isolated CD11b+ cells (I: 
Fig. 9A), indicating the cells respond to an inflammatory stimulus. The basal 
TNF-α secretion was measured after overnight treatment with naloxone 
enantiomers and both enantiomers decreased TNF-α levels in the media by 
15% compared to vehicle treatment (I: Fig 9B). 
5.4 EFFECTS OF POST-STROKE MANF DELIVERY IN 
THE dMCAo MODEL
The neuroprotective protein MANF is a promising drug candidate that has 
shown potential in acute ischemic stroke models. However, in the clinics, the 
drug treatment cannot be given preventively and it is, therefore, vital to study 
post-stroke MANF treatment. 
5.4.1 POST-STROKE PERI-INFARCT TARGETING OF AAV7-MANF AND
rhMANF PROMOTES FUNCTIONAL RECOVERY (II)
 
AAV7-MANF or AAV7-GFP were intracranially injected using peri-infarct 
targeting (Matlik et al., 2014) 2 days after the dMCAo. MANF and GFP were 
robustly expressed in the peri-infarct region already 2 days after the injection 
i.e. 4 days post-stroke (II: Fig. S7A). The AAV7-MANF-treated rats had milder 
neurological deficits measured with Bederson’s score and body asymmetry test 
on d4, d7 and d14 post-stroke (II: Figs. 1D-E, S7B-C) and a trend towards 
better performance in cylinder test (II: Fig. 1F). AAV7-MANF had no effect on 
the infarct volume evaluated by magnetic resonance imaging (II: Fig. 3D-G) or 
histology (II: Figs. S3C-D, S8A). 
In a separate study, rhMANF was chronically infused to the peri-infarct 
area for 14 days starting on d3 post-stroke using mini-osmotic pumps. 
Compared to vehicle, rhMANF-treated rats had milder neurological deficits in 
body asymmetry test at d24 (II: Fig. 2B) and in cylinder test at d14 post-stroke 
(II: Fig. 2C).  
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5.4.2 POST-STROKE PERI-INFARCT TARGETING OF AAV7-MANF 
INDUCES IMMUNOMODULATORY EFFECTS (II)
 
AAV7-MANF treatment increased the mRNA levels of innate immunity-
related genes Emr1 and C3 in the peri-infarct region and the number of CD68 
and arginase 1 (Arg1; a marker for alternative activation of myeloid cells) 
positive cells in the external capsule and dorsal striatum at d4 post-stroke (II: 
Fig. 4A-I). The effect was transient as the number of CD68+ cells was similar 
in AAV7-MANF and AAV7-GFP groups at d14 (II: Fig. S9). At d4, there were 
more MBP and CD68 double-positive cells in the external capsule of AAV7-
MANF-treated rats, indicating increased removal of myelin debris (II: Fig. 
S8C).  
AAV7-MANF had no effect on the mRNA levels of TGF-β1 gene Tgfb1 or 
mannose receptor C-type 1 (Mrc1 a.k.a. CD206) (II: Fig. S10) which are 
considered as marker genes for alternative activation of myeloid cells. There 
were also no differences in the expression of GFAP (II: Fig. S6), MBP (II: Fig. 
S5), laminin, synaptophysin (II: Fig. S4) or NeuN (II: Fig. S3E) in the peri-
infarct area at d14 post-stroke.  
5.4.3 POST-STROKE INTRATHALAMIC rhMANF INJECTION 
ALLEVIATES NEUROLOGICAL DEFICITS (IV)
 
The delayed secondary damage of the thalamus after cortical stroke offers an 
intriguing therapeutic target with a wide therapeutic time window, and we 
aimed to investigate whether the post-stroke recovery can be promoted by 
modulation of the secondary pathology (Figure 14A). We made a single 
intrathalamic recombinant MANF protein injection at post-stroke d7 when 
there is not yet significant neuronal loss in the ipsilateral thalamus (IV; Fig. 
4). We included an additional group treated with the MANF homolog CDNF 
as CDNF has been shown to possess similar neuroprotective effects in acute 
ischemic stroke as MANF (Zhang et al., 2018) and, also, to modulate 
inflammation (Cheng et al., 2013; Nadella et al., 2014; Zhao et al., 2014).  
Compared to vehicle, the CDNF and MANF-treated rats had milder 
neurological deficits at d14 (Figure 14B-C). However, there was no difference 
in the amount of CD68+ cells or neuronal loss in the ipsilateral thalamus at 
d14 (Figure 14D-E). The infarct volume was confirmed to be similar in all 
treatment groups (Figure 14F). The recombinant protein distributed widely 
after the single injection covering the whole ipsilateral thalamus and also parts 
of the striatum (Figure 14G). 
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Figure 14. Post-stroke intrathalamic delivery of MANF protein promotes behavioral 
recovery. A: The rats were divided into groups based on behavioral deficits on day 4 
post-stroke and recombinant CDNF or MANF protein (10 μg) or vehicle was injected 
intrathalamically at 7 days post-stroke. The effects on behavioral recovery and 
secondary pathology were assessed on day 14 post-stroke. B: Body asymmetry test 
and C: Bederson’s score was performed on days 4 and 14 post-stroke (n=8-9;
Kruskal-Wallis test and Mann-Whitney U test). D: The number of CD68+ cells and E:
NeuN+ cells in the ipsilateral thalamus and F: infarct volume were quantified by 
immunohistochemistry at day 14 post-stroke (n=4-6). G: The distribution of 
recombinant human CDNF protein (10 μg) 2h after unilateral intrathalamic injection
shown by anti-hCDNF immunostaining, and illustration of the injection site (A/P -3.0; 
M/L -3.0; D/V -6.0 relative to bregma). * (p<0.05); ** (p<0.01); *** (p<0.001). The data 
represents the mean ± SEM. B, behavioral assay; D, day post-stroke; dMCAo, distal 
middle cerebral artery occlusion; IHC, immunohistochemistry. Figure modified from 
publication IV.
5.5 NEUROPROTECTIVE EFFECTS OF INTRANASAL
MANF DELIVERY IN THE dMCAO MODEL
Intracranial delivery is not a plausible administration route in stroke patients 
when the brain tissue is already compromised and the risk of bleeding is 
increased due to thrombolysis, and therefore alternative delivery routes for 
MANF need to be investigated. A proof-of-concept study was performed using 
the intranasal delivery of recombinant MANF protein for neuroprotection. 
Theoretically, intranasally delivered molecules can bypass the BBB and access 
the CNS from the nasal cavity via the olfactory and trigeminal nerves, vascular 
pathways, cerebrospinal fluid pathways, and lymphatic system [see in (Thorne 
et al., 2004; Hanson & Frey, 2008; Lochhead & Thorne, 2012)]. Using these 
routes systemic metabolism can also be avoided, offering an advantage over 
systemic delivery (Meredith et al., 2015).  
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5.5.1 INTRANASALLY DELIVERED rhMANF REDUCES INFARCT
VOLUME AND BEHAVIORAL DEFICITS (III)
 
Pretreatment with intranasally delivered rhMANF reduced the infarct volume 
by 30% compared to the vehicle group (Figure 15B), especially in the caudal 
brain (Figure 15C). The rhMANF-treated rats had significantly milder 
neurological deficits compared to vehicle-treated rats on d7 and d14 post-
stroke measured with body asymmetry test and Bederson’s score (Figure 15D-
E). 
No differences were found between the groups in cerebral blood flow 
during dMCAo or reperfusion measured with Laser Doppler Flowmetry 
(Figure 15F). We also tested if intranasal MANF treatment would affect the 
BBB integrity by analyzing Evans blue albumin extravasation at 48h after 
dMCAo. There was no difference in Evans blue albumin extravasation into the 
infarct area between the groups (Figure 15G). 
Figure 15. Intranasally delivered MANF protein is neuroprotective. A: Recombinant 
MANF protein (rhMANF; 20 or 60 μg in total) or vehicle was administered intranasally
(indicated by black arrows) to rats 12h before dMCAo, immediately before dMCAo, 
and immediately after reperfusion. Infarct volume and EBA extravasation were
measured 2 days post-stroke. Behavioral recovery was monitored for 14 days in a 
separate experiment. B: Infarct volume measured with TTC staining (Student’s t-test).
C: Distribution of infarct area along the rostrocaudal axis (one-way ANOVA, 
Bonferroni’s post hoc test). Vehicle (n=19), rhMANF (n=25). D: Body asymmetry test 
and E: Bederson’s score (Mann-Whitney U test). F: Cortical cerebral blood flow (CBF) 
was measured with laser Doppler Flowmetry (LDF) before and during ischemia 
(dMCAo) and after reperfusion. Rats received intranasal rhMANF (n=10) or vehicle 
(n=9) immediately before LDF measurement. G: Average Evans blue fluorescence 
intensity on the infarct area 2 days post-dMCAo. * (p<0.05); *** (p<0.001). The data 
represents the mean ± SEM. B, behavioral assay; D, day post-stroke; dMCAo, distal 
middle cerebral artery occlusion; EBA, Evans blue albumin; TTC, 2,3,5-triphenyl-2H-
tetrazolium chloride staining. Unpublished results. 
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5.5.2 DISTRIBUTION OF rhMANF AFTER INTRANASAL DELIVERY (III)
 
The levels of rhMANF in the blood, brain, and liver were analyzed with 125I-
labeled MANF 60 min after the intranasal administration (Figure 16A). 
Approximately 0.4% of the radioactivity of 125I-labeled rhMANF was found in 
the blood, 0.003% in the brain, and 0.08% in the liver (Figure 16B). The levels 
of rhMANF in serum and brain were also analyzed with human MANF ELISA, 
and approximately 0.05% of the total rhMANF dose given was found in the 
serum (Figure 16C). The levels of rhMANF in the brain were under the 
detection limit of ELISA, i.e. below 45 pg/ml.  
Figure 16. Distribution of rhMANF 1h after intranasal delivery. A: 125I-labeled 
recombinant MANF protein (20 ng; 1081152 CPM) together with unlabeled protein 
(20 μg), or vehicle was administered to rats intranasally (indicated by black arrow) 
immediately after dMCAo reperfusion and blood and tissues were collected 60 min 
later. B: Radioactivity counts per minute (CPM) in the rat blood, brain, and liver. C:
Human MANF concentration in rat serum measured by ELISA (Student’s t-test). n=4-
6; * (p<0.05). The data represents the mean ± SEM. dMCAo, distal middle cerebral 
artery occlusion. Unpublished results.
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6 DISCUSSION
6.1 NEUROINFLAMMATION AND ENDOGENOUS MANF 
EXPRESSION AFTER ISCHEMIC STROKE
We show that MANF expression is induced in activated myeloid cells in the 
infarcted brains of both rodents and patients. In the infarcted patient brains, 
the peak expression of phagocytic marker CD68 was observed at two weeks 
after stroke together with the peak MANF expression in the infarct region. In 
rats, the peak CD68 and MANF expression in the infarct core occurred earlier, 
at d7 after stroke, and indeed, it is known that inflammation is more delayed 
in ischemic stroke patients compared to experimental animals (Lindsberg et 
al., 1996). The similar post-stroke expression pattern of MANF in patients and 
experimental animals makes dMCAo a relevant model for studying the role of 
MANF in inflammation and ischemia.  
MANF mRNA is highly expressed in mouse microglia in the healthy brain 
(Zhang et al., 2014) whereas microglial MANF protein expression has been 
found to be very low (Shen et al., 2012). We observed some MANF+ microglial 
cells in the contralateral hemisphere of infarcted rat brains but MANF protein 
translation appears to be strongly induced after ischemia in the activated 
myeloid cells that are mainly microglia/macrophages. The role of MANF 
protein expression in activated myeloid cells and whether it is secreted 
requires further investigation. However, it is intriguing that a cytoprotective 
protein is strongly induced in the immune cells upon injury. If MANF is 
secreted, it could support the injured tissue and provide a pro-reparative 
environment. Additionally, MANF could be needed in the ER for increased 
protein production or for ER remodeling during the activation of myeloid cells. 
The increased protein production in the activated myeloid cells may induce 
UPR and subsequent MANF translation. This is supported by a study by Shen 
et al. where the ER chaperone GRP78 and MANF were both induced in 
activated microglia after ischemia (Shen et al., 2012). Also, a general ER stress 
inducer tunicamycin triggered MANF expression and microglial activation in 
primary microglia cultures (Shen et al., 2012). Moreover, endogenous and 
exogenous MANF are important for neuronal migration (Tseng et al., 2017; 
Tseng et al., 2018), and MANF may be needed in the ER for enabling migration 
of the activated myeloid cells. MANF may also have a role in phagocytosis as 
it is expressed particularly in the round, most reactive state of myeloid cells 
expressing the phagocytic marker CD68, or MANF may be needed for immune 
cell recruitment. We found that overexpression of MANF in the peri-infarct 
area increases the number of CD68+ cells in the same region d4 after dMCAo 
and another study found increased numbers of CD11b+ cells in the damaged 
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retina after intravitreal rhMANF injection (Neves et al., 2016), supporting 
MANF’s role in immune cell recruitment.  
As cerebral MANF protein expression is altered after ischemia in the brain 
and also likely in infiltrating myeloid cells, we explored whether free 
circulating MANF could have potential as a biomarker in ischemic stroke 
diagnostics. However, we found no changes in mouse serum MANF levels 
during the first two days after permanent ischemic stroke and the data do not 
thus support the use of circulating free MANF as a potential biomarker in 
ischemic stroke. The origin of circulating MANF is unknown but at least in the 
case of ischemic stroke, it does not seem to be released from the brain or from 
peripheral myeloid cells to the systemic circulation. 
We observed long-lasting neuroinflammation especially in the ipsilateral 
thalamus lasting up to 4 months after dMCAo. We also investigated the 
secondary neurodegeneration in the thalamus induced by cortical injury and 
found delayed thalamic neuronal loss occurring between d7 and d14 after 
dMCAo. As thalamus has an important role in pain perception and direct 
ischemic injury of the thalamus has been shown to induce thermal 
hypersensitivity (Blasi et al., 2015), we examined if the secondary thalamic 
damage is associated with hyperalgesia but found no difference between the 
stroke and sham animals, implying the damage is not severe enough or is not 
occurring in the neurons participating in the nociceptive signaling. It is not 
known whether the secondary thalamic neuronal loss affects post-stroke 
recovery or whether the persistent presence of activated myeloid cells in the 
infarcted brain is detrimental or beneficial for the recovery. However, these 
CD68+ cells express MANF which could implicate they may have recovery-
promoting effects.  
6.2 POST-STROKE EFFECTS OF NALOXONE
We show intranasal (+)-naloxone treatment started d1 after dMCAo and 
continued for one week reduced behavioral deficits and decreased 
neuroinflammation and infarct size. Interestingly, the behavioral effects of 
(+)-naloxone were not seen until after the treatment was stopped, at d10 and 
d14 post-stroke, even though we observed a reduction in the infarct volume. 
The infarct volume was quantified at d14 but it would seem likely that (+)-
naloxone had neuroprotective effects leading to reduced lesion size already 
within the first couple of days after the dMCAo when the infarct is still 
developing. Therefore, it is surprising that the neurological deficits were 
similar between the groups until d10 post-stroke. The repeated isoflurane 
anesthesia required for the intranasal dosing may have masked the effects of 
(+)-naloxone until the treatment was stopped and the amelioration of 
neurological deficits could be observed. Another explanation for the delayed 
behavioral effect could be the drastic decrease in secondary 
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neuroinflammation and neuronal damage of the thalamus in the (+)-
naloxone-treated animals since these secondary pathology events are initiated 
after d7 post-stroke in the dMCAo model and could hinder the recovery of the 
control animals. 
Naloxone enantiomers inhibit the ROS-producing enzyme NOX2 (Qin et 
al., 2005; Wang et al., 2012), and NOX2 expression has been shown to be 
increased in microglia/macrophages in the infarct core and penumbra 16-24h 
after ischemic stroke (Green et al., 2001; Cooney et al., 2013), around the same 
time point when we started the intranasal naloxone treatment. Interestingly, 
NOX2 expression was shown to decrease by d7 in the ischemic brain (Cooney 
et al., 2013), indicating that we targeted the naloxone treatment for the peak 
expression period. Although the effects of naloxone on TLR4 are unclear, 
TLR4 expression has also been shown to increase between 1-22h after 
ischemic stroke (Hyakkoku et al., 2010). As both NOX2 and TLR4 activation 
have been shown to increase ischemic injury (Cao et al., 2007; Caso et al., 
2007; Tang et al., 2007; Kilic et al., 2008; Kahles & Brandes, 2013), it is likely 
that the intranasal naloxone treatment started at 16-36h after dMCAo was 
neuroprotective through inhibition of either one or both of these target 
proteins. Given the short half-life of naloxone, therapy lasting over the peak 
microglial activation period may be necessary for the neuroprotective effect. 
6.3 POST-STROKE EFFECTS OF MANF
Even though improvement in the neurological deficit scores have been 
traditionally correlated with infarct volume, post-stroke AAV and 
recombinant MANF as well as recombinant CDNF treatment were shown to 
improve the deficits without affecting lesion volume. Currently, the 
mechanism behind this phenomenon cannot be explained and requires further 
investigation. In terms of post-stroke AAV7-MANF therapy, thorough 
histological characterization was performed at d14 but compared to the AAV7-
GFP group, no apparent changes were found in astrogliosis, angiogenesis, 
myelination, or synaptogenesis, the processes associated with post-stroke 
brain repair mechanisms. However, a transient increase in the number of 
phagocytic cells and transcript levels of Emr1 and C3 was found at d4 in the 
peri-lesional areas and we hypothesized that enhanced clearance of debris 
could lead to improved recovery. Better debris clearance could allow improved 
neuroplasticity and functional changes in the peri-infarct area neurons that 
cannot be detected with histological methods. C3 has been shown to regulate 
synaptic plasticity and is involved in immune cell recruitment and 
phagocytosis (Stephan et al., 2012). During development, removal of C3 
results in impaired synaptic connectivity and remodeling (Schafer et al., 
2012). Moreover, the cleavage product of C3, C3a, has been shown to increase 
synaptic plasticity and functional recovery after photothrombotic stroke 
Discussion 
69 
 
(Stokowska et al., 2017). Therefore, the upregulation of C3 may contribute to 
the observed functional improvement after AAV-MANF treatment. 
Recombinant MANF protein infusion to the peri-infarct area has been 
shown to increase the migration of neural progenitor cells into the infarct area 
(Tseng et al., 2018). However, we did not find any differences between the 
AAV7-MANF and AAV7-GFP groups in the number of mature neurons 
(NeuN+ cells) in the peri-infarct areas at d14, suggesting that the mechanism 
of improved recovery after ischemic stroke is not related to neurogenesis in 
the affected cortex. Though, d14 is a very early time point for neurogenesis and 
does not rule out the possibility that MANF could affect neurogenesis later on. 
As an attempt to modulate the secondary pathology of the thalamus, we 
gave a single intrathalamic injection of rhMANF or rhCDNF on d7 after 
dMCAo. No differences were found in the number of neurons or CD68+ cells 
in the thalamus at d14 after dMCAo but the neurological deficits were milder 
in the rhMANF and rhCDNF groups compared to the vehicle group. The 
recovery-promoting mechanism of single post-stroke MANF and CDNF 
protein injection remains elusive but may be a result of enhanced local glia 
function or other effects that would facilitate neurotransmission.  
6.4 INTRANASAL MANF DELIVERY
In an attempt to develop a non-invasive way to administer MANF for stroke 
treatment we used intranasal delivery of recombinant MANF in a 
neuroprotection paradigm. Intranasal delivery of other proteins, such as IGF-
1, erythropoietin, and VEGF, has been shown to be a feasible way for 
neuroprotection in experimental ischemic stroke (Liu et al., 2001; Grasso et 
al., 2007; Buck et al., 2008; Yang et al., 2009) and for passing the BBB (Chen 
et al., 1998; Thorne et al., 2004; Alcala-Barraza et al., 2010). 
Either 20 μg or 60 μg of MANF divided into three doses protected from 
ischemic stroke and ischemia-induced neurological deficits. However, the 
amount of rhMANF found in the brain after intranasal delivery was very low 
and detectable only with radiolabeling of the protein, implying that rhMANF 
would be efficient in only picomolar concentrations in the brain. To verify that 
the detected cerebral radioactivity was indeed from 125I-rhMANF and not from 
free 125I after protein degradation, a more sensitive ELISA method would be 
needed. Also, the calculated bioavailability of 125I-rhMANF in the blood (0.4%) 
was higher compared to the measured bioavailability of unlabeled rhMANF in 
the serum (0.05%) which may suggest either counting of free radioactivity, 
binding of rhMANF to a carrier protein masking the epitopes for ELISA, or 
binding of rhMANF to blood cells that are removed during sera sample 
preparation. 
Since rhMANF was given before ischemia, we measured cortical blood flow 
during ischemia but found no difference compared to vehicle treatment, 
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confirming the neuroprotective effect was not due to improved blood flow. 
Most rhMANF after intranasal delivery was detected in the systemic 
circulation and could also exert neuroprotective effects via systemic 
mechanisms. Given that MANF has been shown to have immunomodulatory 
effects, MANF could mediate its beneficial effects by modulating peripheral 
leukocytes known to play a role in the acute phase of ischemic stroke. We did 
study whether intranasal rhMANF affects the extravasation of Evans blue 
albumin, thought to reflect the leakiness of the BBB, but found no difference 
between rhMANF and vehicle treatment, indicating that the neuroprotective 
mechanism after intranasal rhMANF delivery is not related to decreased BBB 
damage. 
In this thesis, we conducted a proof-of-concept study showing that 
intranasal delivery of rhMANF has neuroprotective effects. We did not use any 
means to increase the nasal absorption, such as adsorption enhancers, and the 
bioavailability of rhMANF was, indeed, very low. Considering the potential 
clinical use of MANF in the future, it is clear that intracranial delivery is not a 
realistic option in routine stroke therapy. Therefore, other delivery routes 
should be considered and intranasal delivery is one potential option shown to 
work clinically with insulin (Reger et al., 2008). However, there are drastic 
differences in the anatomy of nasal pathways and distances within the brain 
between rodents and humans (Lochhead & Thorne, 2012), making intranasal 
delivery far more inefficient in patients and viable only for molecules effective 
in very low concentrations. Another option could be to use the stroke-induced 
disruption of the BBB as a means to deliver BBB-impermeable drugs to the 
infarcted brain from systemic circulation. In the MCAo rat model, leakage of 
large molecules through the BBB has already been reported 25 min after 
reperfusion (Strbian et al., 2008; Abo-Ramadan et al., 2009) and in ischemic 
stroke patients at least between 6-48h after stroke onset (Merali et al., 2017). 
However, rapid degradation of proteins in the systemic circulation and 
potential systemic adverse effects could pose problems in the systemic delivery 
approach, making intranasal delivery a more sophisticated technique in these 
aspects. Collectively, before intranasal rhMANF therapy could be considered 
as a clinical alternative, serious efforts for improving the bioavailability and 
developing an effective formulation would need to be made. 
6.5 TRANSLATIONAL ASPECTS AND FUTURE 
PROSPECTS
Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for 
conducting preclinical stroke studies were created after the massive failure of 
experimental compounds in clinical trials in the 1990s (Stroke Therapy 
Academic Industry, 1999). Lack of internal validity is common in preclinical 
stroke studies and small sample sizes, lack of blinding and randomization, and 
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publication bias have led to an overestimation of the efficacy of 
neuroprotective treatments (Macleod et al., 2008; Kleikers et al., 2015). Also, 
lack of comorbidity in animal models poses translational issues, and at least in 
the case of a free radical scavenger, the efficacy was significantly lower in 
hypertensive rats compared to normotensive (Macleod et al., 2008). It is 
important to perform studies in a blinded and randomized manner in several 
species and in more than one laboratory, in both permanent and transient 
MCAo models, with more than one outcome measure in both acute and long-
term phases (Stroke Therapy Academic Industry, 1999). Furthermore, sex 
differences and toxicology should be comprehensively studied before 
proceeding to clinical trials. STAIR encourages studying multiple 
pharmacological approaches simultaneously as targeting several different 
pathophysiological mechanisms may lead to a more favorable outcome than 
targeting only one mechanism. In this regard, MANF seems like a potential 
molecular probe for a drug candidate as it has several effects. However, the 
immune systems of laboratory mice have been shown to resemble more 
neonatal than adult human (Beura et al., 2016) and housing animals in 
conditions that are too clean may pose translational issues especially when 
assessing the efficacy of immunomodulatory therapies. 
While the STAIR recommendations focused mainly on stroke 
neuroprotection studies, specific guidelines were also created for preclinical 
stroke rehabilitation and recovery studies by the Stroke Recovery and 
Rehabilitation Roundtable (SRRR) (Corbett et al., 2017). The SRRR 
recommendations focus on the importance of relevant long-term outcome 
measures during the months of stroke recovery monitoring, such as finding 
suitable tests for the detection of chronic impairment and implementation of 
brain imaging comparable to clinical practice. 
With keeping these aspects in mind, the therapeutic effect of post-stroke 
MANF and naloxone treatment should be confirmed in female and old animals 
and in a thromboembolic model that better reflects the natural course of 
human infarcts, and preferably also in hypertensive animals to better depict 
the comorbidity in stroke patients. Also, long-term recovery studies should be 
performed using behavioral tests sensitive for detecting chronic impairment. 
Good brain penetration properties and decades of clinical experience make 
naloxone an interesting candidate with relatively newly uncovered anti-
inflammatory effects and the potential of repeated naloxone dosing in 
ischemic stroke patients’ treatment should be considered. 
Also, more studies on the molecular targets of MANF should be conducted 
to reveal the mechanism behind MANF’s recovery-promoting effects. 
Regarding the possible role of MANF in the regulation of immune cell 
function, it would be highly interesting to study whether the recovery from 
stroke is hindered in mice with myeloid cell-specific MANF deletion. Our post-
stroke AAV-MANF data indicate that enhanced removal of tissue debris by 
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phagocytic cells may promote recovery, further contributing to the increasing 
amount of reports supporting pro-reparative functions of immune cells.  Thus, 
future stroke therapies may focus on enhancing these reparative functions of 
immune cells rather than blocking the overall post-stroke inflammation that 
has long been the trend in experimental stroke research. 
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7 CONCLUSIONS
In this thesis work, we aimed to characterize post-stroke neuroinflammation 
in the dMCAo model, including the secondary pathology of the thalamus, and 
MANF protein expression pattern in infarcted human and rodent brain. We 
also investigated pharmacological post-stroke therapies, naloxone and MANF, 
that have been associated with immunomodulatory properties, and conducted 
a proof-of-concept study on non-invasive intranasal MANF therapy. Based on 
this work, the following conclusions can be made: 
 
1) Post-stroke neuroinflammation is long-lasting and present for up to 4 
months after dMCAo, especially in the ipsilateral thalamus. MANF protein 
expression is induced in activated myeloid cells and coexpresses with the 
phagocytic marker CD68 in the infarcted brain regions of patients, rats, 
and mice. 
 
2) Secondary neuronal loss in the ipsilateral thalamus occurs between d7 and 
d14 post-stroke and is not associated with hyperalgesia. Intrathalamic 
injection of MANF or its homolog CDNF on post-stroke d7 has no effect on 
the neuronal loss or the number of CD68+ cells in the thalamus. 
 
3) Post-stroke intranasal (+)-naloxone treatment continued for one week 
reduces behavioral deficits and decreases infarct size and 
microglia/macrophage activation. 
4) Post-stroke AAV-MANF and rhMANF treatment promote functional 
recovery. Post-stroke AAV-MANF modulates inflammation by transiently 
increasing the number of phagocytic CD68+ cells and C3 and Emr1 
transcripts in the peri-infarct area at d4 post-stroke. 
5) Intranasal rhMANF treatment reduces infarct volume and leads to milder 
neurological deficits. 
 
These results mirror the complexity and dual role of post-stroke inflammation 
as we found both the reduction of microglia/macrophage activation with (+)-
naloxone and the increase of phagocytic cells with AAV-MANF promoted 
recovery in the dMCAo model. Post-stroke inflammation is a delicate balance 
between pro-inflammatory and pro-regenerative mechanisms where the 
timing of therapy is essential and both dampening the pro-inflammatory facet 
or boosting the pro-regenerative side can lead to a favorable outcome. 
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